Bovine antibody variants

JP2023551194A5Pending Publication Date: 2024-11-07ZOETIS SERVICES LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530548
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-20
Filing Date
2021-11-19
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

There is a need for improved bovine IgG Fc region mutations to enhance characteristics such as affinity for FcRn, reduce complement-dependent cytotoxicity (CDC), reduce antibody-dependent cytotoxicity (ADCC), and reduce antibody-dependent cellular phagocytosis (ADCP) in veterinary medicine.

Method used

Development of mutant bovine IgGs with specific amino acid substitutions at positions 434, 437, or 433 in the Fc constant region, including modifications like P329S, A330S, P331S, P234A, L235A, G237A, D216E, D270E, L432A, N434A, and T437A, to improve affinity for FcRn and reduce CDC and ADCP.

Benefits of technology

The mutant bovine IgGs exhibit enhanced affinity for FcRn, reduced CDC, and reduced ADCP, providing improved therapeutic efficacy in veterinary applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates generally to bovine antibody variants and their uses. Specifically, the invention relates to mutations in the constant regions of bovine antibodies to improve various characteristics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - reference to Related Applications This application claims the priority and benefit of U.S. Provisional Patent Application No. 63 / 116,491, filed on November 20, 2020, which is hereby incorporated by reference in its entirety.

[0002] The present invention generally relates to bovine antibodies variants and their use. Specifically, the present invention relates to one or more mutations in the Fc constant region of bovine antibodies for improving various characteristics.

Background Art

[0003] Bovine IgG monoclonal antibodies (mAbs) can be effective therapeutic agents in veterinary medicine. A few years ago, three bovine IgG subclasses were identified. However, little research has been done on improving the characteristics of bovine IgG.

[0004] The neonatal Fc receptor (FcRn) extends the half - life of IgG in its pH - dependent interaction with the fragment crystallizable (Fc) region through a recycling mechanism. Specifically, the Fc region that spreads across the interface of the CH2 and CH3 domains interacts with FcRn on the cell surface to regulate IgG constant region. This interaction is favored in the acidic interaction after IgG pinocytosis, and thus IgG is protected from degradation. Then, the endocytosed IgG is recycled to the cell surface and released into the bloodstream at a slightly alkaline pH, thereby maintaining sufficient serum IgG for proper function. Therefore, the pharmacokinetic profiles of IgG depend on the structural and functional properties of their Fc regions.

[0005] The Fc region is also involved in antibody effector functions such as complement-dependent cytotoxicity (CDC), antibody-dependent cytotoxicity (ADCC), and antibody-dependent phagocytosis (ADCP). These effector functions depend on the interaction between the Fc region and FcγR. Therefore, manipulating the Fc region to modulate its interaction with FcγR has emerged as a promising approach to enhance the activity of therapeutic antibodies.

[0006] In human health, decades of Fc engineering have led to the identification of numerous mutations that improve pharmacokinetics and effector function. To date, no such Fc engineering studies have been reported in bovine animals.

[0007] Therefore, there is a need for novel Fc region mutations in bovine IgG to improve various characteristics of bovine IgG. [Overview of the project]

[0008] The present invention relates to mutant bovine IgG exhibiting desired characteristics compared to wild-type bovine IgG. Specifically, the inventors of this application have surprisingly and unexpectedly found that substituting the amino acid residues at positions 216, 234, 235, 237, 270, 329, 330, 331, 432, 434, 437, or 433 (numbered according to the Eu index in Kabat) with another amino acid produced the desired effect. In exemplary embodiments, the unexpected desired effect includes, but is not limited to, improved affinity for FcRn, reduced complement-dependent cytotoxicity (CDC), reduced antibody-dependent cytotoxicity (ADCC), reduced antibody-dependent phagocytosis (ADCP), reduced binding to the Fcγ receptor (bFcgR), or a combination thereof.

[0009] In another embodiment, the present invention provides a modified IgG comprising a bovine IgG constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG constant domain, wherein the substitution is located at amino acid residues 216, 234, 235, 237, 270, 329, 330, 331, 432, 434, 437, or 433.

[0010] In one exemplary embodiment, the bovine IgG constant domain is an IgG1 constant domain containing one or more substitutions from P329S, A330S, P331S, P234A, L235A, G237A, D216E, D270E, L432A, N434A, and T437A.

[0011] In another exemplary embodiment, the bovine IgG constant domain is an IgG2 constant domain containing one or more substitutions from A330S, L432A, N434A, and M437A.

[0012] In yet another exemplary embodiment, the bovine IgG constant domain is an IgG3 constant domain containing one or more substitutions from P329S, A330S, P331S, P234A, L235A, G237A, D270E, L432A, N434A, T437A, and R433H.

[0013] In another embodiment, the present invention provides a polypeptide comprising a bovine IgG constant domain containing one or more amino acid substitutions of the present invention as described herein.

[0014] In another embodiment, the present invention provides an antibody or molecule comprising a bovine IgG constant domain containing one or more amino acid substitutions of the present invention as described herein.

[0015] In a further embodiment, the present invention provides a method for producing or manufacturing an antibody or molecule, the method comprising providing a vector or host cell having a nucleic acid sequence encoding an antibody, wherein the antibody comprises a bovine IgG constant domain comprising one or more amino acid substitutions of the present invention as described herein.

[0016] Other features and advantages of the present invention will become apparent from the examples and drawings in the following detailed description. However, since various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description, it should be understood that the detailed description and specific embodiments are given only as examples, while illustrating preferred embodiments of the present invention.

[0017] Brief explanation of the drawing This patent or application document includes at least one drawing drawn in color. A copy of this patent or patent application publication containing the color drawing will be provided by the Office upon request and payment of the necessary fees. [Brief explanation of the drawing]

[0018] [Figure 1] This diagram illustrates the target cell-killing function induced by IgG-Fc binding to Fcγ receptors on the surface of effector cells. [Figure 2]Sequence alignments are shown for bovine IgG subclasses. Three representative allotypes are shown. The CH1, hinge, CH2, and CH3 domains are as follows: CH1: residues 1-98; hinge: vertical line from 99; CH2: vertical line to 243; CH3: 244-351. Cysteines involved in inter-heavy chain disulfide bonds are shown in bold and underlined. The 3' extension of the CH1 exon in bovine IgG3a is shown in italics. The bold amino acids immediately downstream of the hinge represent the "Winter" or "LALA" site. For bIgG1a and bIgG3a, these sites are LPGG and PLGG, respectively. This site is absent in bIgG2a. The box contains the "PAP" region in bIgG1a and bIgG3a CH2, and the "SAS" region in bIgG2a. The double-underlined arginine (R) in bIgG3a is a residue involved in point mutation to histidine (H). [Figure 3] This shows sequence alignments of three unique alleles from the Bovid IgG1 subclass. Bold: The amino acid "DP" region was mutated on bIgG1a to reduce protease clipping. Underlined: The amino acid was mutated on bIgG1a to knock out effector function. bIgG1d is not included in the bIgG1 allotype alignment because it has the same amino acid sequence as bIgG1b. All mutations performed on bIgG1 are identical to those of the a and b allotypes. [Figure 4]This figure shows the sequence alignment of two reported alleles, bIgG2a (NCBI X16702.1) and bIgG2b (NCBI S82407), from the Bovidae IgG2 subclass to the sequences of IgG2 antibodies isolated from cattle. Bold: Amino acids were mutated on bIgG2a to knock out effector function. The inventors isolated IgG antibodies from dairy cows, and sequencing revealed a two-residue deviation from what was reported for bIgG2a, as shown in Figure 4 as “bIgG2a from cattle sequence.” This sequence may represent a novel allotype of bIgG2, but for the purposes of this patent application, it is referred to as “bIgG2a” due to its nearly identical alignment to bIgG2a. All mutations performed on bIgG2 are identical to the a and b allotypes. [Figure 5] The sequence alignment of two alleles of the bovine IgG3 subclass is shown. Bold: Amino acids mutated on bIgG3a to knock out effector function. Underlined: Residues mutated on bIgG3a to improve affinity for bFcRn. All mutations made to bIgG3 are identical to those in the a and b allotypes. [Figure 6] This shows bovine IgG1a and bIgG1a Fc mutants for knocking out effector function. Bold: Residues involved in the Winter mutation L234A_P235A_G237A*. Box: Residues involved in the PAP to SAS mutation (P329S_P331S*), the PAP to SAP mutation (P329S*), and the PAP to PSS mutation in combination with the Winter mutation (SS mutation; A330S_P331S*). Vertical line: Start of the Fc region in the CTLA4-Fc fusion protein. *Amino acid residues of the mutation are numbered according to the Eu index in Kabat. [Figure 7A] This study demonstrates cell-based complement-dependent cytotoxic activity of bovine IgG1a, IgG1b, and variants of both allotypes. [Figure 7B] This study demonstrates cell-based complement-dependent cytotoxic activity of bovine IgG1a, IgG1b, and variants of both allotypes. [Figure 8] Antibody homology modeling of bIgG1a_WINSAS, bIgG1b_WINSAS, bIgG1c_WINSAS, and bIgG1d_WINSAS is shown. A) Overlay of protein models using enlarged subpanels showing WINSAS residues (arrows). B) Comparison of the root mean square deviation (RMSD) (in angstroms) of WINSAS variants of bIgG1a_WINSAS, bIgG1b_WINSAS, bIgG1c_WINSAS, and bG1d_WINSAS allotypes. [Figure 9] Fc mutations on bovine IgG1a subclass for elimination of antibody - dependent cell - mediated cytotoxicity in cell - based assays are shown. [Figure 10] Analytical SEC of wild - type bovine IgG1a molecule is shown. [Figure 11A] Mass spectrometry analysis of bovine IgG1a wild - type (WT) Fc is shown. [Figure 11B] Mass spectrometry analysis of bovine IgG1a double - mutant DP sites 1 and 2 is shown. [Figure 12] Fc variants from DP to EP of bovine IgG1a and bIgG1a for elimination of cleavage sites are shown. Bold: mutation of "DP1" (site 1) to EP; Underline: mutation of "DP2" (site 2) to EP. [Figure 13] Antibody homology modeling of bIgG1a_DP1_DP2, bIgG1b_DP1_DP2, bIgG1c_DP1_DP2, and bIgG1d_DP1_DP2 is shown. A) Overlay of protein models using enlarged subpanels showing DP1 and DP2 residues (arrows). B) Comparison of the root mean square deviation (RMSD) of DP1_DP2 variants of bovine G1a, G1b, G1c, and G1d allotypes. [Figure 14]This shows bovine IgG2a and bIgG2a Fc mutants for knocking out effector function. First row in bold: Three residues L432*, N434*, and M437* mutated to alanine as independent mutations or combinations. Vertical line: Start of the Fc region in the CTLA4-Fc fusion protein. *Mutated amino acid residues are numbered according to the Eu index in Kabat. [Figure 15A] This study demonstrates that Fc mutations in the bovine IgG2a and IgG2b subclasses eliminate cell-based complement-dependent cytotoxic activity. [Figure 15B] This study demonstrates that Fc mutations in the bovine IgG2a and IgG2b subclasses eliminate cell-based complement-dependent cytotoxic activity. [Figure 16] This shows antibody homology modeling of bIgG2a_L432A_N434A_M437A and bIgG2b_L432A_N434A_M437A. A) Overlay of the protein model using an enlarged subpanel showing the L432A_N434A_M437A residue (arrow). B) Comparison of mean squared deviations (RMSD) of L432A_N434A_M437A mutants of bovine IgG2a and IgG2b allotypes. [Figure 17] This study demonstrates that Fc mutations in the bovine IgG2a subclass eliminate antibody-dependent phagocytosis in cell-based assays. [Figure 18] This shows bovine IgG3a and bIgG3a Fc mutants for knocking out effector function. Bold: Residues involved in the Winter mutation (P234A_L235A_G237A*). Box: Residues involved in the PAP to SAS mutation (P329S_P331S*) and the PAP to SAP mutation (P329S*). Vertical line: Start of the Fc region in the CTLA4-Fc fusion protein. *Amino acid residues of the mutations are numbered according to the Eu index in Kabat. [Figure 19A] This study demonstrates Fc mutations on bovine IgG3a and IgG3b subclasses for the elimination of complement-dependent cytotoxicity in cell-based assays. [Figure 19B]This study demonstrates Fc mutations on bovine IgG3a and IgG3b subclasses for the elimination of complement-dependent cytotoxicity in cell-based assays. [Figure 20] This shows antibody homology modeling of bIgG3a_WINSAS and bIgG3b_WINSAS. A) Overlay of the protein model using an enlarged subpanel showing WINSAS residues (arrows). B) Comparison of mean squared deviations (RMSD) of WINSAS variants of bovine IgG3a and IgG3b allotypes. [Figure 21] This study demonstrates that Fc mutations in the bovine IgG3a subclass eliminate antibody-dependent phagocytosis in cell-based assays. [Figure 22] Bovid IgG3a and Fc mutants for improved bFcRn binding are shown. Bold arginine (R) is the residue involved in the point mutation R433H to histidine (H), numbered according to the Eu index in Kabat. [Figure 23-1] The amino acid sequence alignments for human IgG1, bovine IgG1a, bovine IgG2a, and bovine IgG3a are shown. Amino acid residues are numbered according to the Eu index in Kabat. The amino acid residues of the other alleles of IgG1(b, c, d), IgG2(b), and IgG3(b) shown in Figure 23 are also numbered according to the Eu index. [Figure 23-2] Figure 23 continued. [Figure 23-3] Figure 23 continued. [Figure 23-4] Figure 23 continued. [Figure 23-5] Figure 23 continued.

[0019] A brief explanation of sequence listings Sequence ID 1 refers to the amino acid sequence of IgG1a wild type (NCBI ID number 1S82409).

[0020] Sequence ID 2 refers to the amino acid sequence of IgG1b wild-type (NCBI ID number X16701).

[0021] Sequence ID 3 refers to the amino acid sequence of IgG1c wild type (NCBI ID number DQ452014.1).

[0022] Sequence ID 4 refers to the amino acid sequence of IgG1d wild type (NCBI ID number X62916.1).

[0023] Sequence ID 5 refers to the amino acid sequence of IgG2a wild type (NCBI ID number X16702.1).

[0024] Sequence ID 6 refers to the amino acid sequence of IgG2b wild type (NCBI ID number S82407).

[0025] Sequence ID 7 refers to the amino acid sequence of IgG3a wild type.

[0026] Sequence ID 8 refers to the amino acid sequence of IgG3b wild type.

[0027] Sequence ID 9 refers to the amino acid sequence of wild-type IgG2a derived from dairy cows.

[0028] Sequence ID 10 refers to the amino acid sequence of IgG1a with the DP1 mutation.

[0029] Sequence ID 11 refers to the amino acid sequence of IgG1a with the DP2 mutation.

[0030] Sequence ID 12 refers to the amino acid sequence of IgG1a with DP1 and DP2 mutations.

[0031] Sequence ID 13 refers to the amino acid sequence at physical positions 99-329 of the IgG1a wild-type fragment.

[0032] Sequence ID 14 refers to the amino acid sequence of an IgG1a fragment containing the SAP mutation.

[0033] Sequence ID 15 refers to the amino acid sequence of an IgG1a fragment containing the SAS mutation.

[0034] Sequence ID 16 refers to the amino acid sequence of an IgG1a fragment containing the Winter mutation.

[0035] Sequence ID 17 refers to the amino acid sequence of an IgG1a fragment containing Winter and SAS mutations.

[0036] Sequence ID 18 refers to the amino acid sequence of an IgG1a fragment containing Winter and SS mutations.

[0037] Sequence ID 19 refers to the amino acid sequence of IgG2a having mutation L432A.

[0038] Sequence ID 20 refers to the amino acid sequence of IgG2a having mutation N434A.

[0039] Sequence ID 21 refers to the amino acid sequence of IgG2a containing the mutation M437A.

[0040] Sequence ID 22 refers to the amino acid sequence of IgG2a containing mutations L432A and M437A.

[0041] Sequence ID 23 refers to the amino acid sequence of IgG2a containing mutations N434A and M437A.

[0042] Sequence ID 24 refers to the amino acid sequences of IgG2a having mutations L432A, N434A, and M437A.

[0043] Sequence ID 25 refers to the amino acid sequence of IgG2a having mutations L432A and N434A.

[0044] Sequence ID 26 refers to the amino acid sequence at physical positions 99-352 of the IgG3a wild-type fragment.

[0045] Sequence ID 27 refers to the amino acid sequence of an IgG3a fragment containing the SAP mutation.

[0046] Sequence ID 28 refers to the amino acid sequence of an IgG3a fragment containing the SAS mutation.

[0047] Sequence ID 29 refers to the amino acid sequence of an IgG3a fragment containing the Winter mutation.

[0048] Sequence ID 30 refers to the amino acid sequence of an IgG3a fragment containing Winter and SAS mutations.

[0049] Sequence ID 31 refers to the amino acid sequence of IgG3a containing the mutation R433H.

[0050] Sequence ID 32 refers to the amino acid sequence of human IgG1.

[0051] Sequence ID 33 refers to the amino acid sequence of IgG1b wild type.

[0052] Sequence ID 34 refers to the nucleic acid sequence of IgG1b wild type.

[0053] Sequence ID 35 refers to the amino acid sequence of IgG1b containing the Winter mutation.

[0054] Sequence ID 36 refers to the nucleic acid sequence of IgG1b containing the Winter mutation.

[0055] Sequence ID 37 refers to the amino acid sequence of IgG1b with the WinSS mutation.

[0056] Sequence ID 38 refers to the nucleic acid sequence of IgG1b containing the WinSS mutation.

[0057] Sequence ID 39 refers to the amino acid sequence of IgG1b with the WinSAS mutation.

[0058] Sequence ID 40 refers to the nucleic acid sequence of IgG1b containing the WinSAS mutation.

[0059] Sequence ID 41 refers to the amino acid sequence of IgG1b with the SAS mutation.

[0060] Sequence ID 42 refers to the nucleic acid sequence of IgG1b with the SAS mutation.

[0061] Sequence ID 43 refers to the amino acid sequence of IgG1b containing the SAP mutation.

[0062] Sequence ID 44 refers to the nucleic acid sequence of IgG1b containing the SAP mutation.

[0063] Sequence ID 45 refers to the amino acid sequence of IgG1b with the D216E mutation.

[0064] Sequence ID 46 refers to the nucleic acid sequence of IgG1b containing the D216E mutation.

[0065] Sequence ID 47 refers to the amino acid sequence of IgG1b with the D270E mutation.

[0066] Sequence ID 48 refers to the nucleic acid sequence of IgG1b containing the D270E mutation.

[0067] Sequence ID 49 refers to the amino acid sequence of IgG1b with D216E and D270E mutations.

[0068] Sequence ID 50 refers to the nucleic acid sequence of IgG1b containing the D216E and D270E mutations.

[0069] Sequence ID 51 refers to the amino acid sequence of IgG2b wild type.

[0070] Sequence ID 52 refers to the nucleic acid sequence of IgG2b wild type.

[0071] Sequence ID 53 refers to the amino acid sequence of IgG2b with the L432A mutation.

[0072] Sequence ID 54 refers to the nucleic acid sequence of IgG2b having the L432A mutation.

[0073] Sequence ID 55 refers to the amino acid sequence of IgG2b with the N434A mutation.

[0074] Sequence ID 56 refers to the nucleic acid sequence of IgG2b containing the N434A mutation.

[0075] Sequence ID 57 refers to the amino acid sequence of IgG2b with the M437A mutation.

[0076] Sequence ID 58 refers to the nucleic acid sequence of IgG2b containing the M437A mutation.

[0077] Sequence ID 59 refers to the amino acid sequence of IgG2b with L432A and N434A mutations.

[0078] Sequence ID 60 refers to the nucleic acid sequence of IgG2b having L432A and N434A mutations.

[0079] Sequence ID 61 refers to the amino acid sequence of IgG2b with L432A and M437A mutations.

[0080] Sequence ID 62 refers to the nucleic acid sequence of IgG2b containing the L432A and M437A mutations.

[0081] Sequence ID 63 refers to the amino acid sequence of IgG2b with N434A and M437A mutations.

[0082] Sequence ID 64 refers to the nucleic acid sequence of IgG2b containing the N434A and M437A mutations.

[0083] Sequence ID 65 refers to the amino acid sequence of IgG2b having the L432A, N434A, and M437A mutations.

[0084] Sequence ID 66 refers to the nucleic acid sequence of IgG2b having the L432A, N434A, and M437A mutations.

[0085] Sequence ID 67 refers to the amino acid sequence of IgG3b wild type.

[0086] Sequence ID 68 refers to the nucleic acid sequence of IgG3b wild type.

[0087] Sequence ID 69 refers to the amino acid sequence of IgG3b containing the Winter mutation.

[0088] Sequence ID 70 refers to the nucleic acid sequence of IgG3b containing the Winter mutation.

[0089] Sequence ID 71 refers to the amino acid sequence of IgG3b with the WinSAS mutation.

[0090] Sequence ID 72 refers to the nucleic acid sequence of IgG3b containing the WinSAS mutation.

[0091] Sequence ID 73 refers to the amino acid sequence of IgG3b with the SAS mutation.

[0092] Sequence ID 74 refers to the nucleic acid sequence of IgG3b containing the SAS mutation.

[0093] Sequence ID 75 refers to the amino acid sequence of IgG3b containing the SAP mutation.

[0094] Sequence ID 76 refers to the nucleic acid sequence of IgG3b containing the SAP mutation.

[0095] Sequence ID 77 refers to the amino acid sequence of IgG3b with the R433H mutation.

[0096] Sequence ID 78 refers to the nucleic acid sequence of IgG3b having the R433H mutation.

[0097] Sequence ID 79 refers to the adjacent amino acid sequence from bIgG1bWin(L234A_P235A_G237A):LPGG to AAGA.

[0098] Sequence ID 80 refers to the adjacent amino acid sequence from bIgG1bWin(L234A_P235A_G237A):LPGG to AAGA.

[0099] Sequence ID 81 refers to the adjacent amino acid sequence from PAP to PSS: bIgG1bWinSS(A330S_P331S).

[0100] Sequence ID 82 refers to the adjacent nucleic acid sequence from PAP to PSS: bIgG1bWinSS(A330S_P331S).

[0101] Sequence ID 83 refers to the adjacent amino acid sequence from PAP to SAS in bIgG1bSAS(P329S_P331S):PAP.

[0102] Sequence ID 84 refers to the adjacent amino acid sequence from PAP to SAS in bIgG1bSAS(P329S_P331S):PAP.

[0103] Sequence ID 85 refers to the adjacent amino acid sequence from PAP to SAP: bIgG1bSAP(P329S).

[0104] Sequence ID 86 refers to the adjacent amino acid sequence from PAP to SAP in bIgG1bSAP(P329S):PAP.

[0105] Sequence ID 87 refers to the adjacent amino acid sequence from DP1 to EP1: bIgG1b_DP1(D216E).

[0106] Sequence ID 88 refers to the adjacent amino acid sequence from DP1 to EP1: bIgG1b_DP1(D216E).

[0107] Sequence ID 89 refers to the adjacent amino acid sequence from DP2 to EP2: bIgG1b_DP2(D270E).

[0108] Sequence ID 90 refers to the adjacent amino acid sequence from DP2 to EP2: bIgG1b_DP2(D270E).

[0109] Sequence ID 91 refers to the adjacent amino acid sequence from bIgG2b_L432A:LHNHYM to AHNHYM.

[0110] Sequence ID 92 refers to the adjacent amino acid sequence from bIgG2b_L432A:LHNHYM to AHNHYM.

[0111] Sequence ID 93 refers to the adjacent amino acid sequence from bIgG2b_N434A:LHNHYM to LHAHYM.

[0112] Sequence ID 94 refers to the adjacent amino acid sequence from bIgG2b_N434A:LHNHYM to LHAHYM.

[0113] Sequence ID 95 refers to the adjacent amino acid sequence from bIgG2b_M437A:LHNHYM to LHNHYA.

[0114] Sequence ID 96 refers to the adjacent amino acid sequence from bIgG2b_M437A:LHNHYM to LHNHYA.

[0115] Sequence ID 97 refers to the adjacent amino acid sequences from bIgG2b_L432A_N434A:LHNHYM to AHNHYM and from LHNHYM to LHAHYM.

[0116] Sequence ID 98 refers to the adjacent amino acid sequences from bIgG2b_L432A_N434A:LHNHYM to AHNHYM and from LHNHYM to LHAHYM.

[0117] Sequence ID 99 refers to the adjacent amino acid sequences from bIgG2b_L432A_M437A:LHNHYM to AHNHYM and from LHNHYM to LHNHYA.

[0118] Sequence ID 100 refers to the adjacent amino acid sequences from bIgG2b_L432A_M437A:LHNHYM to AHNHYM and from LHNHYM to LHNHYA.

[0119] Sequence ID 101 refers to the adjacent amino acid sequences from bIgG2b_N434A_M437A:LHNHYM to LHAHYM, and from LHNHYM to LHNHYA.

[0120] Sequence ID 102 refers to the adjacent amino acid sequences from bIgG2b_N434A_M437A:LHNHYM to LHAHYM, and from LHNHYM to LHNHYA.

[0121] Sequence ID 103 refers to the adjacent amino acid sequences from bIgG2b_L432A_N434A_M437A:LHNHYM to AHNHYM, LHNHYM to LHAHYM, and LHNHYM to LHNHYA.

[0122] Sequence ID 104 refers to the adjacent amino acid sequences from bIgG2b_L432A_N434A_M437A:LHNHYM to AHNHYM, LHNHYM to LHAHYM, and LHNHYM to LHNHYA.

[0123] Sequence ID 105 refers to the adjacent amino acid sequence AAGA from bIgG3bWin(P234A_L235A_G237A):PLGG.

[0124] Sequence ID 106 refers to the adjacent amino acid sequence AAGA from bIgG3bWin(P234A_L235A_G237A):PLGG.

[0125] Sequence ID 107 refers to the adjacent amino acid sequence from PAP to SAS in bIgG3bSAS(P329S_P331S):PAP.

[0126] Sequence ID 108 refers to the adjacent amino acid sequence from PAP to SAS: bIgG3bSAS(P329S_P331S).

[0127] Sequence ID 109 refers to the adjacent amino acid sequence from PAP to SAP: bIgG3bSAP(P329S).

[0128] Sequence ID 110 refers to the adjacent amino acid sequence from PAP to SAP in bIgG3bSAP(P329S):PAP.

[0129] Sequence ID 111 refers to the adjacent amino acid sequence from bIgG3b_R433H:ALRNH to ALHNH.

[0130] Sequence ID 112 refers to the adjacent amino acid sequence from bIgG3b_R433H:ALRNH to ALHNH.

[0131] Sequence ID 113 refers to the amino acid sequence of biotin acceptor peptide (BAP). [Modes for carrying out the invention]

[0132] [000154] The subject matter of the present invention can be more readily understood by referring to the following detailed description which forms part of this disclosure. The present invention is not limited to the specific products, methods, conditions, or parameters described and / or shown herein, and it should be understood that the terms used herein are for illustrative purposes only to illustrate specific embodiments and are not intended to limit the claimed invention.

[0133] [000155] Unless otherwise defined herein, scientific and technical terms used in connection with this application shall have meanings generally understood by those skilled in the art. Furthermore, unless otherwise required by the context, singular terms shall include plural forms and plural terms shall include singular forms.

[0134] [000156] When used above and throughout this disclosure, the following terms and abbreviations shall be understood to have the following meanings unless otherwise indicated.

[0135] definition [000157] In this disclosure, the singular forms “a,” “an,” and “the” include plural references, and references to specific numerical values ​​include at least that specific value unless the context clearly indicates otherwise. Thus, for example, references to “molecules” or “compounds” refer to one or more such molecules or compounds and their equivalents known to those skilled in the art. The term “plural” as used herein means more than one. Where a range of values ​​is expressed, an alternative embodiment includes one specific value and / or other specific values. Similarly, where a value is expressed as an approximation, it is understood that by using the preceding “about,” a specific value forms an alternative embodiment. All ranges are comprehensive and combinable.

[0136] [000158] In this specification and in the claims, the numbering of amino acid residues in immunoglobulin heavy chains is the Eu index in Kabat, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). "Kabat's Eu index" refers to the residue numbering of IgG antibodies, which is reflected in Figure 23 in this specification.

[0137] [000159] The term “isolated,” when used in reference to nucleic acids, refers to nucleic acids that are identified and separated from nucleic acids that are typically associated with at least one contaminant in their natural source. Isolated nucleic acids are in a different form or configuration than those found in nature. Thus, isolated nucleic acid molecules are distinguished from nucleic acid molecules present in natural cells. Isolated nucleic acid molecules include nucleic acid molecules contained within cells that normally express the polypeptide they encode, for example, nucleic acid molecules in plasmid or chromosomal locations different from those in natural cells. Isolated nucleic acids can exist in single-stranded or double-stranded form. When proteins are expressed using isolated nucleic acid molecules, oligonucleotides or polynucleotides contain minimal sense strands or coding strands, but may contain both sense and antisense strands (i.e., they may be double-stranded).

[0138] [000160] A nucleic acid molecule is “operably linked” or “operably bound” when it is positioned in a functional relationship with another nucleic acid molecule. For example, a promoter or enhancer is operably linked to the coding sequence of a nucleic acid when it affects the transcription of the sequence, or a ribosome binding site is operably linked to the coding sequence of a nucleic acid when it is positioned to facilitate translation. If the fusion protein to be expressed is positioned to include a heterologous protein or a functional fragment thereof adjacent either upstream or downstream of the variant Fc region polypeptide, the nucleic acid molecule encoding the variant Fc region is operably linked to the nucleic acid molecule encoding the heterologous protein (i.e., a protein or a functional fragment thereof that does not contain the Fc region as it would naturally exist), and the heterologous protein may be adjacent to the variant Fc region polypeptide in the immediate vicinity or separated from it by a linker sequence of any length and composition. Similarly, a polypeptide molecule (as used herein synonymously with “protein”) is “operably linked” or “operably bound” when it is positioned in a functional relationship with another polypeptide.

[0139] [000161] As used herein, the term “functional fragment” refers, when referring to a polypeptide or protein (e.g., a variant Fc region or a monoclonal antibody), to a fragment of that protein that retains at least one function of the full-length polypeptide. The fragment may be in size from six amino acids to the entire amino acid sequence of the full-length polypeptide minus one amino acid. The functional fragments of the variant Fc region polypeptide of the present invention retain at least one “amino acid substitution” as defined herein. The functional fragments of the variant Fc region polypeptide retain at least one function known in the art to be associated with the Fc region (e.g., ADCC, CDC, Fc receptor binding, Clq binding, downregulation of cell surface receptors, or, for example, increasing the in vivo or in vitro half-life of the polypeptide to which it is operably bound).

[0140] [000162] The terms “purified” or “purify” refer to the substantial removal of at least one contaminant from a sample. For example, antigen-specific antibodies can be purified by the complete or substantial removal (at least 90%, 91%, 92%, 93%, 94%, 95%, or more preferably at least 96%, 97%, 98%, or 99%) of at least one contaminant, non-immunoglobulin protein, and can also be purified by the removal of immunoglobulin proteins that do not bind to the same antigen. The removal of non-immunoglobulin proteins and / or immunoglobulins that do not bind to a particular antigen results in an increase in the percentage of antigen-specific immunoglobulins in the sample. In another example, polypeptides expressed in bacterial host cells (e.g., immunoglobulins) can be purified by the complete or substantial removal of host cell proteins, thereby increasing the percentage of polypeptides in the sample.

[0141] [000163] The term “natural” is used herein to indicate that a polypeptide (e.g., an Fc region) has an amino acid sequence that is naturally present or a naturally present polymorph of such polypeptide. Natural polypeptides (e.g., natural Fc regions) can be produced by recombinant means or isolated from natural sources.

[0142] [000164] As used herein, the term “expression vector” refers to a recombinant DNA molecule containing a desired coding sequence and a suitable nucleic acid sequence necessary for the expression of an operablely linked coding sequence in a particular host organism.

[0143] [000165] As used herein, the term “host cell” means any eukaryotic or prokaryotic cell, whether configured in vitro, in situ, or in vivo (e.g., bacterial cells such as E. coli, CHO cells, yeast cells, mammalian cells, avian cells, amphibian cells, plant cells, fish cells, and insect cells).

[0144] [000166] As used herein, the term “Fc region” refers to the C-terminal region of an immunoglobulin heavy chain. The “Fc region” may be a native sequence Fc region or a variant Fc region. While the generally acceptable boundaries of the Fc region of an immunoglobulin heavy chain may vary, the Fc region of a bovine IgG heavy chain is typically defined as the range from the vertical line to the c-terminus in Figure 2, for example. In some embodiments, a variant may consist only of a portion of the Fc region and may or may not include a carboxyl terminus. The Fc region of an immunoglobulin generally consists of two constant domains, CH2 and CH3. In some embodiments, a variant having one or more of these constant domains is intended. In other embodiments, a variant having no such constant domains (or only a portion of such constant domains) is intended.

[0145] [000167] The "CH2 domain" in the Fc region of bovine IgG refers, for example, to the residues starting from the vertical line in Figure 2 and extending to residue 243. The CH2 domain is unique in that it does not closely pair with another domain. Two N-linked branched carbohydrate chains are interposed between the two CH2 domains of the original natural IgG molecule.

[0146] [000168] The "CH3 domain" of the Fc region of bovine IgG generally corresponds to the residues from the C-terminus of the Fc region to the CH2 domain, for example, the residues from 244 to the c-terminus in Figure 2.

[0147] [000169] A “functional Fc region” has “effector function” of a native sequence Fc region. Examples of effector functions include, but are not limited to, C1q binding; complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), and downregulation of cell surface receptors (e.g., B cell receptors; BCRs). Such effector functions may require the Fc region to be operably linked to a binding domain (e.g., an antibody-variable domain) and can be evaluated using various assays (e.g., Fc binding assays, ADCC assays, CDC assays, ADCP assays, target cell depletion from whole blood samples or fractionated blood samples).

[0148] [000170] The term "natural sequence Fc region" or "wild-type Fc region" refers to an amino acid sequence that is identical to the amino acid sequence of a naturally occurring and commonly found Fc region. An example of a natural sequence bovid Fc region is from the vertical line to the c-terminus in Figure 2.

[0149] [000171] A “variant Fc region” contains an amino acid sequence that differs from that of the natural sequence Fc region (or a fragment thereof) due to at least one “amino acid substitution” as defined herein. In a preferred embodiment, the variant Fc region has at least one amino acid substitution, preferably one, two, three, four, or five amino acid substitutions, compared to the natural sequence Fc region or the Fc region of the parent polypeptide. In an alternative embodiment, the variant Fc region may be generated according to the methods disclosed herein, and this variant Fc region may be fused to an antibody variable domain or a non-antibody polypeptide, such as a selected heterologous polypeptide, including a receptor or ligand binding domain.

[0150] [000172] As used herein, the term “derivative” in the context of polypeptides refers to a polypeptide comprising an amino acid sequence modified by the introduction of amino acid residue substitutions. As used herein, the term “derivative” also refers to a polypeptide modified by the covalent bonding of any type of molecule to the polypeptide. For example, antibodies may be modified by, for example, glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins. Derivative polypeptides may be produced by chemical modification using techniques known to those skilled in the art, including, but not limited to, specific chemical cleavage, acetylation, formylation, and metabolic synthesis of tunicamycin. Furthermore, derivative polypeptides have the same or identical function as the polypeptide from which they were derived. Polypeptides comprising the variant Fc region of the present invention may be derivatives as defined herein, and preferably, it is understood that derivatization takes place within the Fc region.

[0151] [000173] When used herein in relation to polypeptides (e.g., Fc regions or monoclonal antibodies), “substantially of bovine origin” means that the polypeptide has an amino acid sequence that is at least 80%, at least 85%, more preferably at least 90%, 91%, 92%, 93%, 94%, or even more preferably at least 95%, 96%, 97%, 98%, or 99% homologous to that of a natural bovine aminopolypeptide.

[0152] [000174] The terms “Fc receptor” or “FcR” are used to describe receptors that bind to an Fc region (e.g., the Fc region of an antibody). Preferred FcRs are natural sequence FcRs. Furthermore, preferred FcRs include receptors of the FcγRI(FcgR1), FcγRII(FcgR2), FcγRIII(FcgR3) subclasses that bind to the IgG antibody Fc region, Fcγ receptor, or “FcgR (Fc gamma receptor)” and include allelic variants and alternatively spliced ​​forms of these receptors, as well as novel bovine Fcγ2R(bFcg2R or bFcg2R). Another preferred FcR is FcRn, the neonatal receptor responsible for the transfer of maternal IgG to the fetus (Guyer et al., J.Immunol. 117:587 (1976) and Kim et al., J.Immunol. 24:249 (1994)). Other FcRs, including those to be identified in the future, are encompassed herein by the term “FcR”.

[0153] [000175] The terms “antibody-dependent cell-mediated cytotoxicity” and “ADCC” refer to a cell-mediated reaction in which nonspecific cytotoxic cells expressing FcgR (e.g., nonspecific) (e.g., natural killer ("NK") cells, neutrophils, and macrophages) recognize antibodies bound to target cells, and subsequently cause lysis of the target cells. In humans, NK cells, which are the primary cells for mediating ADCC, express only FcgR3, while monocytes express FcgR1, FcgR2, and FcgR3. According to the literature, bovine monocytes and macrophages express FcgR for IgG1 and IgG2 isotypes, while neutrophils express many receptors for IgG2 and Fcg2R, but little to no expression for bIgG1.

[0154] [000176] The terms “antibody-dependent cell-mediated phagocytosis” and “ADCP” refer to a cell-mediated response in which phagocytic cells expressing FcgR (e.g., macrophages, monocytes, dendritic cells) (e.g., FcgR1, FcgR2a, and FcgR3) recognize the Fc region of an IgG antibody bound to a target cell, and subsequently trigger a signaling cascade that leads to the phagocytosis of IgG-opsonized particles (e.g., bacteria, dead tissue cells).

[0155] [000177] As used herein, the term “effector cell” refers to a leukocyte (preferably from a bovine animal) that expresses one or more FcRs and performs effector function. Preferably, the cell expresses at least FcgR3 and performs ADCC effector function. Examples of leukocytes that mediate ADCC include PBMCs, NK cells, monocytes, macrophages, cytotoxic T cells, and neutrophils. Effector cells can be isolated from natural sources (e.g., blood or PBMCs). In one example, a leukocyte expresses FcgR1 or other relevant Fcγ receptor and induces ADCC function.

[0156] [000178] A variant polypeptide having “modified” Fc receptor binding affinity has either improved (i.e., increased, greater, or higher) or decreased (i.e., reduced, decreased, or lower) Fc receptor binding affinity compared to the variant’s parent polypeptide or a polypeptide containing natural Fc. A variant polypeptide exhibiting increased binding to the Fc receptor or increased binding affinity binds to the Fc receptor with greater affinity than the parent polypeptide. A variant polypeptide exhibiting decreased binding to the Fc receptor or decreased binding affinity binds to the Fc receptor with lower affinity than its parent polypeptide. Such a variant exhibiting decreased binding to the Fc receptor may have little to no binding to the Fc receptor, for example, 0-20% binding to the Fc receptor compared to the parent polypeptide. When the amounts of the variant polypeptide and parent polypeptide in the binding assay are essentially the same and all other conditions are identical, a variant polypeptide that binds to the Fc receptor with “improved affinity” compared to its parent polypeptide binds to the Fc receptor with higher binding affinity than the parent polypeptide. For example, when Fc receptor binding affinity is determined by an ELISA assay or other method available to those skilled in the art, a variant polypeptide having improved Fc receptor binding affinity may show an increase of approximately 1.10 to 100 times (more typically, approximately 1.2 to 50 times) in Fc receptor binding affinity compared to the parent polypeptide.

[0157] [000179] As used herein, “amino acid substitution” means replacing at least one existing amino acid residue in a given amino acid sequence with another different “substitution” amino acid residue. The substitution residue or more substitution residues may be “naturally occurring amino acid residues” (i.e., encoded by the genetic code) and are selected from alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine ​​(Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile):leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), and valine (Val). Substitution with one or more non-naturally occurring amino acid residues is also included in the definition of amino acid substitution herein. "Naturally unexisting amino acid residues" refer to residues other than the naturally occurring amino acid residues listed above, and can be covalently bonded to adjacent amino acid residues within a polypeptide chain. Examples of naturally unexisting amino acid residues include norleucine, ornithine, norvaline, homoserine, and other amino acid residue analogs, such as those described in Ellman et al. Meth. Enzym. 202:301-336 (1991).

[0158] [000180] The term “assay signal” refers to the output from any method for detecting protein-protein interactions, including, but not limited to, colorimetric assays, fluorescence intensity, or absorbance measurements from decays per minute. Assay formats may include ELISA, FACS, or other methods. Changes in “assay signal” may reflect changes in cell viability, and / or changes in kinetic off-rate, kinetic on-rate, or both. A “higher assay signal” refers to a number of measured outputs greater than another (e.g., a variant may have a higher (greater) number of measurements in an ELISA assay compared to its parent polypeptide). A “lower” assay signal refers to a number of measured outputs less than another (e.g., a variant may have a lower (smaller) number of measurements in an ELISA assay compared to its parent polypeptide).

[0159] [000181] The term "binding affinity" refers to the equilibrium dissociation constant (expressed in units of concentration) associated with each Fc receptor-Fc binding interaction. Binding affinity is expressed in units of kinetic off-rate (generally the reciprocal of time, e.g., seconds). -1 It is directly related to the ratio obtained by dividing the (reported in) by the dynamic on-rate (generally reported in units of concentration per unit time, e.g., moles / second). Generally, unless each of these parameters is determined experimentally (e.g., by BIACORE or SAPIDYNE measurements), the equilibrium dissociation constant (K) is relevant. D It is impossible to definitively state whether the change in KD (or KD) is due to the difference between on-rate, off-rate, or both.

[0160] [000182] As used herein, the term “hinge region” refers to the range of amino acids that link the Fab antigen-binding region to the Fc region of the antibody. The hinge region of an IgG subclass can be aligned by placing the first and last cysteine ​​residues that form the inter-heavy-chain disulfide (SS) bond in the same position. As shown in Figure 2, for example, the hinge region in the constant region of bovine IgG begins at residue 99 and extends to the vertical line.

[0161] [000183] "C1q" is a polypeptide that contains a binding site for the Fc region of immunoglobulin. C1q, together with two serine proteases, C1r and C1s, forms complex C1, which is the first component of the CDC pathway.

[0162] [000184] As used herein, the term “antibody” is used synonymously with “immunoglobulin” or “Ig” and is used in the broadest sense to specifically encompass monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, insofar as they exhibit the desired biological or functional activity. Single-chain antibodies containing portions derived from different species, and chimeric, bovine, or bovinized antibodies, as well as single-chain antibodies transplanted with chimeric or CDRs, are also included in the present invention and the term “antibody.” These various portions of antibodies can be chemically and synthetically joined together by conventional techniques or prepared as a continuous protein using genetic engineering techniques. For example, nucleic acids encoding chimeric or bovinized chains can be expressed to produce a continuous protein. For example, see U.S. Patent Nos. 4,816,567, 4,816,397, WO86 / 01533, 5,225,539, 5,585,089, and 5,698,762. For primate antibodies, see Newman, R. et al., BioTechnology, 10:1455-1460, 1993, and for single-chain antibodies, see Ladner et al., U.S. Patent No. 4,946,778 and Bird, R. et al., Science, 242:423-426, 1988. In this specification, all forms of antibodies containing an Fc region (or a portion thereof) are understood to be encompassed within the term “antibody.” Furthermore, antibodies can be labeled with detectable labels, immobilized on a solid phase, and / or conjugated with heterologous compounds (e.g., enzymes or toxins) according to methods known in the art.

[0163] [000185] As used herein, the term “antibody fragment” refers to a portion of an antibody as is. Examples of antibody fragments include, but are not limited to, linear antibodies; single-chain antibody molecules; Fc or Fc' peptides, Fab and Fab fragments; and multispecific antibodies formed from antibody fragments. The antibody fragment preferably retains at least a portion of the hinge and optionally the CH1 region of the IgG heavy chain. In other preferred embodiments, the antibody fragment includes at least a portion of the CH2 region or the entire CH2 region.

[0164] [000186] As used herein, the term “functional fragment” is intended to refer to a portion of a monoclonal antibody that still retains functional activity, when used in reference to a monoclonal antibody. Functional activity may be, for example, antigen-binding activity or specificity, receptor-binding activity or specificity, effector functional activity, etc. Examples of monoclonal antibody functional fragments include individual heavy or light chains such as VL, VH, and Fd, and their fragments; monovalent fragments such as Fv, Fab, and Fab'; bivalent fragments such as F(ab')2; single-chain Fv(scFv); and Fc fragments. Such terminology is described, for example, in Harlowe and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989), Molec. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, RA (ed.), New York: VCH Publisher, Inc.), Huston et al., Cell Biophysics, 22:189-224 (1993), Pluckthun and Skerra, Meth. Enzymol., 178:497-515 (1989), and Day, ED, Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc., New York, NY (1990). The term functional fragment is intended to include, for example, fragments produced by protease digestion or reduction of monoclonal antibodies and by recombinant DNA methods known to those skilled in the art.

[0165] [000187] As used herein, the term “fragment” refers to a polypeptide comprising an amino acid sequence of at least 5, 15, 20, 25, 40, 50, 70, 90, 100 or more consecutive amino acid residues of the amino acid sequence of another polypeptide. In preferred embodiments, the polypeptide fragment retains at least one function of the full-length polypeptide.

[0166] [000188] As used herein, the term “chimeric antibody” includes monovalent, bivalent, or polyvalent immunoglobulins. A monovalent chimeric antibody is a dimer formed by a chimeric heavy chain associated with a chimeric light chain via a disulfide crosslink. A bivalent chimeric antibody is a tetramer formed by two heavy-light chain dimers associated with at least one disulfide crosslink. The chimeric heavy chain of an antibody for use in bovids includes an antigen-binding region derived from a non-bovid antibody heavy chain, which is linked to at least a portion of the constant region (CL) of the bovid light chain. The chimeric light chain of an antibody for use in bovids includes an antigen-binding region derived from a non-bovid antibody light chain, which is linked to at least a portion of the constant region (CL) of the bovid light chain. Antibodies, fragments, or derivatives having the same or different chimeric heavy and light chains of variable region binding specificity can also be prepared by appropriate association of individual polypeptide chains according to known method steps. Using this approach, a host expressing a chimeric light chain and a host expressing a chimeric heavy chain are cultured separately, the immunoglobulin chains are recovered separately, and then they are assembled. Alternatively, the hosts may be co-cultured, the chains may be spontaneously assembled in the culture medium, and then the assembled immunoglobulin or fragments may be recovered, or both the heavy and light chains may be expressed in the same host cells. Methods for generating chimeric antibodies are well known in the art (see, for example, U.S. Patents 6,284,471, 5,807,715, 4,816,567, and 4,816,397).

[0167] [000189] As used herein, a “bovine” form of a non-bovine (e.g., mouse) antibody (i.e., a bovine antibody) is an antibody that contains minimal or no sequences derived from non-bovine immunoglobulins. In most cases, a bovine antibody is a bovine immunoglobulin (recipient antibody) in which residues from the hypervariable region of the recipient are replaced by residues from the hypervariable region of a non-bovine species (donor antibody), such as mouse, rat, rabbit, human, or non-human primate, having the desired specificity, affinity, and capability. In some cases, framework region (FR) residues of the bovine immunoglobulin are replaced by corresponding non-bovine residues. Furthermore, a bovine antibody may contain residues not found in the recipient antibody or donor antibody. These modifications are generally made to further improve antibody performance. Generally, bovine antibodies contain substantially all of at least one, typically two, variable domains, with all or substantially all of the hypervariable loop (CDR) corresponding to that of a non-bovine immunoglobulin, and all or substantially all of the FR residues being from a bovine immunoglobulin sequence. Bovine antibodies may also contain at least a portion of the immunoglobulin constant region (Fc), typically that of a bovine immunoglobulin.

[0168] [000190] As used herein, the term “immunoadhesin” refers to an antibody-like molecule that combines the binding domain of a heterogeneous “adhesin” protein (e.g., a receptor, ligand, or enzyme) with an immunoglobulin constant domain. Structurally, an immunoadhesin comprises a fusion of an immunoadhesin amino acid sequence having desired binding specificity, which is other than the antigen recognition and binding site (antigen binding site) of an antibody (i.e., “heterogeneous”), and an immunoglobulin constant domain sequence.

[0169] [000191] As used herein, the term “ligand-binding domain” means any intrinsic receptor, or any region or derivative thereof, that retains at least the qualitative ligand-binding ability of the corresponding intrinsic receptor. In certain embodiments, the receptor is derived from a cell surface polypeptide having an extracellular domain homologous to a member of the immunoglobulin supergene family. Other receptors that are not members of the immunoglobulin supergene family but are nevertheless specifically covered by this definition are cytokine receptors, in particular receptors with tyrosine kinase activity (receptor tyrosine kinases), members of the hematopoietin and nerve growth factor receptor superfamilies, and cell adhesion molecules (e.g., E-, L-, and P-selectins).

[0170] [000192] As used herein, the term “receptor-binding domain” means any natural ligand of a receptor, for example, a cell adhesion molecule, or any region or derivative of such a natural ligand that retains at least the qualitative receptor-binding ability of the corresponding natural ligand.

[0171] [000193] As used herein, “isolated” polypeptide is a polypeptide that has been identified and separated from its natural environment components and / or recovered. Contaminating components from its natural environment are substances that would interfere with the diagnostic or therapeutic use of the polypeptide and include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In certain embodiments, the isolated polypeptide is purified to (1) more than 95% by weight, preferably more than 99% by weight, of the polypeptide by the Lowry method, (2) to a degree sufficient to obtain at least 15 residues of the N-terminal or internal amino acid sequence by using a rotating cup sequencer, or (3) to homogeneity by SDS-page under reducing or non-reducing conditions using Coomassie blue or silver staining. The isolated polypeptide includes the polypeptide in situ within recombinant cells, since at least one component of the polypeptide’s natural environment would be absent. However, typically, the isolated polypeptide will be prepared by at least one purification step.

[0172] [000194] As used herein, the terms “disorder” and “disease” are used synonymously to refer to any condition that would benefit from treatment with a variant polypeptide (a polypeptide comprising the variant Fc region of the present invention), including chronic and acute disorders or diseases (e.g., pathological conditions that predispose a patient to a particular disorder).

[0173] [000195] As used herein, the term “receptor” refers to a polypeptide capable of binding to at least one ligand. Preferred receptors are cell surface or soluble receptors having an extracellular ligand-binding domain and, optionally, other domains (e.g., a transmembrane domain, an intracellular domain, and / or a membrane anchor). The receptors evaluated in the assays described herein may be the receptor as is, or fragments or derivatives thereof (e.g., fusion proteins containing a receptor-binding domain fused to one or more heterologous polypeptides). Furthermore, the receptors evaluated for their binding properties may be present intracellularly or isolated, and may optionally be coated onto assay plates or some other solid phases, or directly labeled and used as probes.

[0174] [000196] As used herein, a variant polypeptide that knocks out or knocks down antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) in the presence of bovine effector cells compared to a parent antibody is substantially less active in vitro or in vivo in mediating ADCC, ADCP, and / or CDC when the amounts of the variant polypeptide and parent antibody used in the assay are essentially the same. For example, such a variant causes a lower, preferably negligible, amount of target cell lysis or phagocytosis in a given ADCC, ADCP, or CDC assay than the parent polypeptide in the same ADCC assay. Such a variant may be identified, for example, using an ADCC, ADCP, or CDC assay, but other assays or methods for determining ADCC, ADCP, or CDC activity may also be used (e.g., animal models). In a preferred embodiment, the variant polypeptide has about 100, 75, 50, or 25 percent less activity in mediating ADCC, ADCP, and CDC than the parent polypeptide.

[0175] Wild-type IgG of Bovidae animals [000197] Bovid IgG is well known in the art and is fully described, for example, in Symons et al., 1989, Mol.Immunol., vol.26(9), pages 841-850, Kacskovics et al., 1996, Mol.Immunol., vol.33(2), pages 189-195, Saini et al., 2007, Scand.J.Immunol., vol.65(1), pages 32-38, and Rabbani et al., 1997, Immunogenetics, vol.46(4), pages 326-331.

[0176] [000198] In one embodiment, the bovine IgG is IgG1. In another embodiment, the bovine IgG is IgG2. In yet another embodiment, the bovine IgG is IgG3. In one example, IgG1 is IgG1a, IgG1b, IgG1c, or IgG1d. In another example, IgG2 is IgG2a or IgG2b. In yet another example, IgG3 is IgG3a or IgG3b.

[0177] [000199] The amino acid sequences and nucleic acid sequences of IgG1a, IgG1b, IgG1c, IgG1d, IgG2a, IgG2b, IgG3a, and IgG3b are also well known in the art.

[0178] [000200] In one example, the IgG of the present invention includes a constant domain, for example, a CH1, CH2, or CH3 domain, or a combination thereof. In another example, the constant domain of the present invention includes an Fc region, for example, a CH2 or CH3 domain, or a combination thereof.

[0179] [000201] In certain examples, the wild-type constant domain includes one of the amino acid sequences described in SEQ ID NOs: 1 to 8. In certain embodiments, the wild-type constant domains of IgG1a, IgG1b, IgG1c, IgG1d, IgG2a, IgG2b, IgG3a, and IgG3b include the amino acid sequences described in SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, and 8, respectively. In some embodiments, the wild-type IgG constant domain is a homolog, variant, isomer, or functional fragment of one of SEQ ID NOs: 1 to 8, but does not have any of the mutations described herein. Each possibility represents a distinct embodiment of the present invention. For example, in one embodiment, in a certain embodiment, the wild-type constant domain of IgG2a includes the amino acid sequence described in SEQ ID NO: 9.

[0180] [000202] The IgG contain domain also comprises a polypeptide having an amino acid sequence substantially similar to the amino acid sequences of the heavy chain and / or light chain. A substantially identical amino acid sequence is defined herein as a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity with the compared amino acid sequence, as determined by the FASTA search method in accordance with Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988).

[0181] [000203] The present invention also includes nucleic acid molecules encoding IgG or a portion thereof as described herein. In one embodiment, the nucleic acid may encode an antibody heavy chain comprising, for example, a CH1, CH2, CH3 region, or a combination thereof. In another embodiment, the nucleic acid may encode an antibody heavy chain comprising, for example, one of the VH region or a portion thereof, or one of the VH CDRs, comprising any variant thereof. The present invention also includes nucleic acid molecules encoding an antibody light chain comprising, for example, one of the CL region or a portion thereof, one of the VL region or a portion thereof, or one of the VL CDRs, comprising any variant thereof. In a particular embodiment, the nucleic acid encodes both the heavy chain and the light chain, or both portions thereof.

[0182] [000204] The amino acid sequences of the wild-type constant domains described in Sequence IDs 1, 2, 3, 4, 5, 6, 7, 8 and 9 are encoded by their corresponding nucleic acid sequences.

[0183] Modified Bovid IgG [000205] The inventors of this application have found, surprisingly and unexpectedly, that substituting the amino acid residues at positions 216, 234, 235, 237, 270, 329, 330, 331, 432, 434, 437, or 433 with another amino acid produced the desired effect. As used herein, the term position refers to a position numbered according to the EU index in Kabat (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). In one embodiment, the desired effect is to eliminate or reduce complement-dependent cytotoxicity compared to IgG having a wild-type bovine IgG constant domain. In another embodiment, the desired effect is to eliminate or reduce antibody-dependent phagocytosis compared to IgG having a wild-type bovine IgG constant domain. In yet another embodiment, the desired effect is to eliminate or reduce the binding of IgG to the Fcγ receptor (bFcgR).

[0184] [000206] In one embodiment, the present invention provides a modified IgG comprising a bovine IgG constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG constant domain, wherein the substitution is located at amino acid residues 216, 234, 235, 237, 270, 329, 330, 331, 432, 434, 437, or 433, numbered according to the Eu index in Kabat. The amino acids at these positions may be substituted with any other amino acids. Examples of substituted amino acids include, but are not limited to, asparagine, histidine, serine, alanine, phenylalanine, glycine, isoleucine, lysine, leucine, methionine, glutamine, arginine, threonine, valine, tryptophan, tyrosine, cysteine, aspartic acid, glutamic acid, and proline. In some embodiments, the substituted amino acid is a non-natural amino acid.

[0185] [000207] The modified bovine IgG of the present invention may be any suitable bovine IgG known to those skilled in the art. Examples of modified bovine IgG include modified variants of IgG1 (e.g., IgG1a, IgG1b, IgG1c, or IgG1d), IgG2 (e.g., IgG2a or IgG2b), or IgG3 (IgG3a or IgG3b).

[0186] IgG1 [000208] In one exemplary embodiment, the modified bovine IgG is a modified bovine IgG1 that includes, for example, modified IgG1a, modified IgG1b, modified IgG1c, or modified IgG1d.

[0187] [000209] In one embodiment, the present invention provides a modified IgG1 comprising a bovine IgG1 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG1 constant domain, wherein the substitution is located at amino acid residues 329, 330, 331, or a combination thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at positions 329, 330, or 331 may be substituted with any other amino acid. In certain embodiments, the substitution is a serine substitution. Specifically, in one example, the substitution is a serine substitution of proline at position 329 (P329S), a serine substitution of alanine at position 330 (A330S), or a serine substitution of proline at position 331 (P331S). In some embodiments, the modified bovine IgG1 constant domain comprises one or more of the substitutions P329S, A330S, and P331S.

[0188] [000210] In one embodiment, the modified bovine IgG1 constant domain includes PAP-to-SAP mutations, PAP-to-SAS mutations, SS mutations, Winter site mutations, or combinations thereof. PAP-to-SAP mutations include the substitution of proline with serine at position 329 (P329S). SS mutations include the substitution of alanine with serine at position 330 (A330S) and the substitution of proline with serine at position 331 (P331S).

[0189] [000211] The Winter region may include substitutions at amino acid residues 234, 235, 237, or combinations thereof. Thus, in another embodiment, the present invention provides a modified IgG1 comprising a bovine IgG1 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG1 constant domain, wherein the substitution is at amino acid residues 234, 235, or 237, or combinations thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at positions 234, 235, or 237 may be substituted with any other amino acid. In certain embodiments, the substitution is a substitution with alanine. Specifically, in one example, the substitution is a substitution of proline with alanine at position 234 (P234A), a substitution of leucine with alanine at position 235 (L235A), or a substitution of glycine with alanine at position 235 (G237A). In some embodiments, the modified bovine IgG1 constant domain includes one or more of the substitutions P234A, L235A, and G237A.

[0190] [000212] In exemplary embodiments, the bovine IgG1 constant domain includes one or more of the substitutions P329S, A330S, P331S, P234A, L235A, and G237A.

[0191] [000213] In one embodiment, the modified bovine IgG1 constant domain includes a substitution at an amino acid residue in the DP site. Thus, in another embodiment, the present invention provides a modified IgG1 comprising a bovine IgG1 constant domain which includes at least one amino acid substitution compared to the wild-type bovine IgG1 constant domain, wherein the substitution is at amino acid residues 216, 270, or a combination thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at position 216 or 270 may be substituted with any other amino acid. In certain embodiments, the substitution is a substitution with glutamic acid. Specifically, in one example, the substitution is a substitution of glutamic acid of aspartic acid at position 216 (D216E) or a substitution of glutamic acid of aspartic acid at position 270 (D270E). In some embodiments, the modified bovine IgG1 constant domain includes one or more substitutions D216E and D270E.

[0192] [000214] In exemplary embodiments, the bovine IgG1 constant domain includes one or more of the substitutions P329S, A330S, P331S, P234A, L235A, G237A, D216E, and D270E.

[0193] [000215] In another embodiment, the present invention provides a modified IgG1 comprising a bovine IgG1 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG1 constant domain, wherein the substitution is located at amino acid residues 432, 434, 437, or a combination thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at positions 432, 434, or 437 may be substituted with any other amino acid. In a particular embodiment, the substitution is a substitution with alanine. Specifically, in one example, the substitution is a substitution of leucine with alanine at position 432 (L432A), a substitution of asparagine with alanine at position 434 (N434A), and a substitution of threonine with alanine at position 437 (T437A). In some embodiments, the modified bovine IgG1 constant domain includes one or more substitutions L432A, N434A, and T437A.

[0194] [000216] In another exemplary embodiment, the bovine IgG1 constant domain includes one or more of the substitutions P329S, A330S, P331S, P234A, L235A, G237A, D216E, D270E, L432A, N434A, and T437A.

[0195] IgG2 [000217] In another exemplary embodiment, the modified bovine IgG is a modified bovine IgG2, which includes, for example, modified IgG2a or modified IgG2b. The modified bovine IgG2 may include SS mutations, which include a substitution of alanine with serine at position 330 (A330S) and a substitution of proline with serine at position 331 (P331S). In one embodiment, the present invention provides a modified IgG2 comprising a bovine IgG2 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG2 constant domain, wherein the substitution is at amino acid residues 330, 331, or a combination thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at position 330 or 331 may be substituted with any other amino acid. In a particular embodiment, the substitution is a substitution with serine. Specifically, in one example, the substitution is the substitution of alanine with serine at position 330 (A330S) or the substitution of proline with serine at position 331 (P331S). In some embodiments, the modified bovine IgG2 constant domain contains one or more of the substitutions A330S and P331S.

[0196] [000218] In another embodiment, the present invention provides a modified IgG2 comprising a bovine IgG2 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG2 constant domain, wherein the substitution is located at amino acid residues 432, 434, 437, or a combination thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at positions 432, 434, or 437 may be substituted with any other amino acid. In a particular embodiment, the substitution is a substitution with alanine. Specifically, in one example, the substitution is a substitution of leucine with alanine at position 432 (L432A), a substitution of asparagine with alanine at position 434 (N434A), or a substitution of methionine with alanine at position 437 (M437A). In some embodiments, the modified bovine IgG2 constant domain includes one or more substitutions from L432A, N434A, and M437A.

[0197] [000219] In another exemplary embodiment, the bovine IgG2 constant domain includes one or more of the substitutions A330S, L432A, N434A, and M437A.

[0198] IgG3 [000220] In another exemplary embodiment, the modified bovine IgG is a modified bovine IgG3, which includes, for example, modified IgG3a or modified IgG3b.

[0199] [000221] In one embodiment, the present invention provides a modified IgG3 comprising a bovine IgG3 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG3 constant domain, wherein the substitution is located at amino acid residues 329, 330, 331, or a combination thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at positions 329, 330, or 331 may be substituted with any other amino acid. In certain embodiments, the substitution is a serine substitution. Specifically, in one example, the substitution is a serine substitution of proline at position 329 (P329S), a serine substitution of alanine at position 330 (A330S), or a serine substitution of proline at position 331 (P331S). In some embodiments, the modified bovine IgG3 constant domain comprises one or more of the substitutions P329S, A330S, and P331S.

[0200] [000222] In one embodiment, the modified bovine IgG3 constant domain includes mutations from PAP to SAP, mutations from PAP to SAS, SS mutations, Winter site mutations, or combinations thereof. As described above, the mutation from PAP to SAP includes a substitution of proline with serine at position 329 (P329S), the mutation from PAP to SAS includes a substitution of proline with serine at position 331 (P331S), and the SS mutation includes a substitution of alanine with serine at position 330 (A330S) in combination with a substitution of proline with serine at position 331 (P331S).

[0201] [000223] As described above, the Winter region may include substitutions at amino acid residues 234, 235, 237, or combinations thereof. Accordingly, in another embodiment, the present invention provides a modified IgG3 comprising a bovine IgG3 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG3 constant domain, wherein the substitution is at amino acid residues 234, 235, or 237, or combinations thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at positions 234, 235, or 237 may be substituted with any other amino acid. In certain embodiments, the substitution is a substitution with alanine. Specifically, in one example, the substitution is a substitution of proline with alanine at position 234 (P234A), a substitution of leucine with alanine at position 235 (L235A), or a substitution of glycine with alanine at position 235 (G237A). In some embodiments, the modified bovine IgG3 constant domain includes one or more of the substitutions P234A, L235A, and G237A.

[0202] [000224] In exemplary embodiments, the bovine IgG3 constant domain includes one or more of the substitutions P329S, A330S, P331S, P234A, L235A, and G237A.

[0203] [000225] In one embodiment, the modified bovine IgG3 constant domain includes a substitution at an amino acid residue in the DP site. Thus, in another embodiment, the present invention provides a modified IgG3 comprising a bovine IgG3 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG3 constant domain, wherein the substitution is at amino acid residue 270, and the amino acid residue position is numbered according to the Eu index in Kabat. The amino acid residue at position 270 may be substituted with any other amino acid. In a particular embodiment, the substitution is a substitution with glutamic acid. Specifically, in one example, the substitution is a substitution of glutamic acid with aspartic acid at the aspartic acid position at position 270 (D270E).

[0204] [000226] In exemplary embodiments, the bovine IgG3 constant domain includes one or more of the substitutions P329S, A330S, P331S, P234A, L235A, G237A, and D270E.

[0205] [000227] In another embodiment, the present invention provides a modified IgG3 comprising a bovine IgG3 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG3 constant domain, wherein the substitution is located at amino acid residues 432, 434, 437, or a combination thereof, and the amino acid residue positions are numbered according to the Eu index in Kabat. The amino acid residue at positions 432, 434, or 437 may be substituted with any other amino acid. In certain embodiments, the substitution is a substitution with alanine. Specifically, in one example, the substitution is a substitution of leucine with alanine at position 432 (L432A), a substitution of asparagine with alanine at position 434 (N434A), or a substitution of lysine with alanine at position 437 (K437A). In some embodiments, the modified bovine IgG1 constant domain comprises one or more substitutions L432A, N434A, and K437A.

[0206] [000228] In another exemplary embodiment, the bovine IgG3 constant domain includes one or more of the substitutions P329S, A330S, P331S, P234A, L235A, G237A, D270E, L432A, N434A, and K437A.

[0207] [000229] Accordingly, in yet another embodiment, the present invention provides a modified IgG3 comprising a bovine IgG3 constant domain comprising at least one amino acid substitution compared to the wild-type bovine IgG3 constant domain, wherein the substitution is located at amino acid residue 433, and the amino acid residue position is numbered according to the Eu index in Kabat. The amino acid residue at position 433 may be substituted with any other amino acid. In a particular embodiment, the substitution is a substitution with histidine. Specifically, in one embodiment, the substitution is a substitution of asparagine with histidine at position 433 (R433H).

[0208] [000230] In yet another exemplary embodiment, the bovine IgG3 constant domain includes one or more of the substitutions P329S, A330S, P331S, P234A, L235A, G237A, D270E, L432A, N434A, K437A, and R433H.

[0209] [000231] In certain examples, the mutant IgG1 constant domain of the present invention comprises any one of the amino acid sequences described in SEQ ID NOs: 10-12 and 14-18. In some embodiments, the mutant IgG1 constant domain is a homolog, variant, isomer, or functional fragment of any one of SEQ ID NOs: 10-12 and 14-18, but having the mutation of the present invention as described herein. Each possibility represents a distinct embodiment of the present invention.

[0210] [000232] In another example, the mutant IgG2 constant domain of the present invention comprises any one of the amino acid sequences described in SEQ ID NOs. 19-25. In some embodiments, the mutant IgG2 constant domain is a homolog, variant, isomer, or functional fragment of any one of SEQ ID NOs. 19-25, but having the mutation of the present invention as described herein. Each possibility represents a distinct embodiment of the present invention.

[0211] [000233] In certain examples, the mutant IgG3 constant domain of the present invention comprises any one of the amino acid sequences described in SEQ ID NOs. 27-31. In some embodiments, the mutant IgG3 constant domain is a homolog, variant, isomer, or functional fragment of any one of SEQ ID NOs. 27-31, but having the mutation of the present invention as described herein. Each possibility represents a distinct embodiment of the present invention.

[0212] [000234] The amino acid sequences of the mutant constant domains described in Sequence IDs 10-12, 14-25, and 27-31 are encoded by their corresponding mutant nucleic acid sequences.

[0213] Method for producing antibody molecules of the present invention [000235] Methods for producing antibody molecules are well known in the art and are fully described in U.S. Patents 8,394,925, 8,088,376, 8,546,543, 10,336,818, and 9,803,023, and U.S. Patent Application Publication 2006 / 0067930, which are incorporated herein by reference in their entirety. Any preferred method, process, or technique known to those skilled in the art may be used. Antibody molecules having the variant Fc region of the present invention can be produced according to methods well known in the art. In some embodiments, the variant Fc region can be fused to a selected heterologous polypeptide, such as the antibody variable domain or binding domain of a receptor or ligand.

[0214] [000236] With the advent of molecular biology methods and recombinant techniques, those skilled in the art can generate antibodies and antibody-like molecules by recombinant means, thereby generating gene sequences encoding specific amino acid sequences found in the polypeptide structure of antibodies. Such antibodies can be produced by either cloning the gene sequence encoding the polypeptide chain of the antibody, or by directly synthesizing the polypeptide chain and assembling the synthesized chain to form an active tetramer (H2L2) structure having affinity for a specific epitope and antigenic determinant. This has made it possible to immediately generate antibodies having sequences characterized by neutralizing antibodies from different species and sources.

[0215] [000237] Regardless of how antibodies are recombinantly constructed or synthesized, whether in vitro or in vivo, using transgenic animals which are laboratory-sized or commercially available large cell cultures, using transgenic plants, or by direct chemical synthesis without the use of living organisms at any stage of the process, all antibodies have a similar three-dimensional structure overall. This structure is often provided as H2L2, referring to the fact that antibodies generally contain two light chain (L) amino acids and two heavy chain (H) amino acids. Both chains have regions capable of interacting with structurally complementary antigen targets. The regions that interact with targets are referred to as “variable” or “V” regions and are characterized by differences in the amino acid sequence from antibodies with different antigen specificities. The variable region of either the H or L chain contains an amino acid sequence capable of specifically binding to an antigen target.

[0216] [000238] As used herein, the term “antigen-binding region” refers to a portion of an antibody molecule that contains amino acid residues that interact with an antigen and confer its specificity and affinity to the antigen to the antibody. The antibody-binding region includes “framework” amino acid residues necessary to maintain the proper three-dimensional structure of the antigen-binding residue. Within the variable region of the H or L chain that provides the antigen-binding region, there is a smaller sequence called “hypervariable,” which is the reason for the extreme variability between antibodies of different specificities. Such hypervariable regions are also called “complementarity-determining regions” or “CDR regions.” These CDR regions are responsible for the fundamental specificity of the antibody to a particular antigenic determinant structure.

[0217] [000239] CDRs represent discontinuous ranges of amino acids within the variable region, but it has been found that, regardless of species, the positions where these important amino acid sequences are located within the variable heavy and light chain regions are similar within the amino acid sequence of the variable chain. All antibody variable heavy and light chains each have three CDR regions, each discontinuous with the others. In all mammalian species, antibody peptides contain constant (i.e., highly conserved) regions and variable regions, the latter of which include CDRs and so-called "framework regions" consisting of amino acid sequences that are within the variable region of the heavy or light chain but outside the CDRs.

[0218] [000240] The present invention further provides vectors comprising at least one of the nucleic acids described above. Since the genetic code is degraded, two or more codons may be used to code for a particular amino acid. Using the genetic code, one or more different nucleotide sequences may be identified, each of which may be capable of coding for an amino acid. The probability that a particular oligonucleotide will actually constitute an actual coding sequence can be estimated by considering the unusual base pairing relationships in the eukaryotic or prokaryotic cells expressing the antibody or portion, and the frequency with which a particular codon is actually used (to code for a particular amino acid). Such “codon usage rules” are disclosed by Lathe, et al., 183 J. Molec. Biol. 1-12 (1985). Using Lathe’s “codon usage rules,” it is possible to identify a single nucleotide sequence or set of nucleotide sequences containing the theoretically “most likely” nucleotide sequence capable of coding for a bovine IgG sequence. It is also intended that antibody coding regions for use in the present invention may also be provided by modifying existing antibody genes using standard molecular biological techniques that produce variants of the antibodies and peptides described herein. Such variants include, but are not limited to, deletions, additions, and substitutions in the amino acid sequence of an antibody or peptide.

[0219] [000241] For example, one category of substitutions is conserved amino acid substitutions. Such substitutions replace a given amino acid in a bovine antibody peptide with another amino acid having similar characteristics. Typical examples of conserved substitutions include the exchange of aliphatic amino acids Ala, Val, Leu, and lie; the exchange of hydroxyl residues Ser and Thr; the exchange of acidic residues Asp and Glu; the exchange of amide residues Asn and Gin; the exchange of basic residues Lys and Arg; and the exchange of aromatic residues Phe and Tyr. Guidance on which amino acid changes are likely to be phenotypic silent can be found in Bowie et al., 247 Science 1306-10 (1990).

[0220] [000242] Variant Bovidae antibody or peptide may be fully functional or lack function in one or more activities. Fully functional variants typically contain only conserved mutations or mutations in non-essential residues or regions. Functional variants may also contain similar amino acid substitutions that do not alter function or alter it slightly. Alternatively, such substitutions may have a positive or negative effect to some extent. Non-functional variants typically contain one or more non-conserved amino acid substitutions, deletions, insertions, inversions, or cleavages, or substitutions, insertions, inversions, or deletions in essential residues or regions.

[0221] [000243] Amino acids essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine scanning mutagenesis. Cunningham et al., 244 Science 1081-85 (1989). The latter procedure introduces a single alanine mutation into all residues in the molecule. The resulting mutant molecule is then tested for biological activity, such as epitope binding or in vitro ADCC activity. Sites important for ligand-receptor binding can also be determined by structural analysis such as epitope mapping (e.g., HDX), crystallography, nuclear magnetic resonance, or photoaffinity labeling. Smith et al., 224 J.Mol.Biol.899-904 (1992), de Vos et al., 255 Science 306-12 (1992).

[0222] [000244] Furthermore, polypeptides often contain amino acids other than the 20 “naturally occurring” amino acids. Moreover, many amino acids, including terminal amino acids, can be modified by natural processes such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent bonding of flavins, covalent bonding of heme moieties, covalent bonding of nucleotides or nucleotide derivatives, covalent bonding of lipids or lipid derivatives, covalent bonding of phosphotidylinositol, crosslinking, cyclization, disulfide bond formation, demethylation, covalent crosslinking, cystine formation, pyroglutamate formation, formylation, gammacarboxylation, glycosylation, GPI anchor formation, hydroxylation, iodization, methylation, myristoylation, oxidation, proteolysis, phosphorylation, prenylation, racemization, selenoylation, sulfation, arginylation, and other transfer-RNA mediated additions of amino acids to proteins, as well as ubiquitination. Such modifications are well known to those skilled in the art and are described in detail in the scientific literature. Several particularly common modifications, such as glycosylation, lipid attachment, sulfated proteins, gamma-carboxylation, hydroxylation, and ADP-ribosylation of glutamate residues, are described in the most basic textbooks, for example, *Proteins - Structure and Molecular Properties* (2nd ed., TECreighton, WH Freeman & Co., NY, 1993). Numerous detailed reviews on this subject are available, including those by Wold, *Posttranslational Covalent Modification of Proteins*, 1-12 (Johnson, ed., Academic Press, NY, 1983), Seifter et al. 182 *Meth. Enzymol.* 626-46 (1990), and Rattan et al. 663 *Ann. NY Acad. Sci.* 48-62 (1992).

[0223] [000245] In another aspect, the present invention provides antibody derivatives. “Derivatives” of antibodies typically contain additional chemical portions that are not part of the protein. Covalent modifications of proteins are within the scope of the present invention. Such modifications can be introduced into a molecule by reacting target amino acid residues of an antibody with an organic derivatizing agent that can react with selected side chain or terminal residues. For example, derivatization using bifunctional agents well known in the art is useful for crosslinking antibodies or fragments to a water-insoluble support matrix or other macromolecule carrier.

[0224] [000246] The derivatives also include radiolabeled monoclonal antibodies to be labeled. For example, radioactive iodine (251,1311), carbon (4C), sulfur (35S), indium, tritium (H 3 ) etc; conjugates of monoclonal antibodies containing biotin or avidin with enzymes such as horseradish peroxidase, alkaline phosphatase, beta-D-galactosidase, glucose oxidase, glucoamylase, carboxylic acid anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase, or glucose-6-phosphate dehydrogenase; and also conjugates of monoclonal antibodies with bioluminescent agents (such as luciferase), chemiluminescent agents (such as acridine esters), or fluorescent agents (such as phycovir protein).

[0225] [000247] Another derivative bifunctional antibody of the present invention is a bispecific antibody produced by combining two separate antibody portions that recognize two different antigenic groups. This can be achieved by crosslinking or recombinant techniques. In addition, the portion can be added to the antibody or a portion thereof to increase the in vivo half-life (for example, by extending the time to clearance from the bloodstream). Such a technique is, for example, the addition of a PEG portion (also called pegylation), which is well known in the art. See U.S. Patent Application Publication No. 2003 / 0031671.

[0226] [000248] In some embodiments, the nucleic acid encoding the antibody of the subject is directly introduced into host cells, and the cells are incubated under conditions sufficient to induce the expression of the encoded antibody. After the nucleic acid of the subject is introduced into the cells, the cells are typically incubated for a period of about 1 to 24 hours, usually at 37°C, sometimes under selective conditions, to allow antibody expression. In one embodiment, the antibody is secreted into the supernatant of the culture medium in which the cells are growing. Conventionally, monoclonal antibodies have been produced as innate molecules in mouse hybridoma strains. In addition to that technique, the present invention provides recombinant DNA expression of antibodies. This enables the production of antibodies in selected host species, as well as the generation of spectra of antibody derivatives and fusion proteins.

[0227] [000249] The nucleic acid sequences encoding at least one antibody, moiety, or polypeptide of the present invention may be recombined with vector DNA according to conventional techniques including blunt or overhanging ends for ligation, restriction enzyme digestion to provide suitable ends, proper packing of sticky ends, alkaline phosphatase treatment to avoid undesirable binding, and ligation with a suitable ligase. Techniques for such operations are disclosed, for example, by Maniatis et al., MOLECULAR CLONING, LAB. MANUAL, (Cold Spring Harbor Lab. Press, NY, 1982 and 1989) and Ausubel et al. 1993 (above), and these can be used to construct nucleic acid sequences encoding an antibody molecule or its antigen-binding region.

[0228] [000250] Nucleic acid molecules such as DNA contain nucleotide sequences that contain transcriptional and translational regulatory information, and such sequences are said to be "capable of expressing" polypeptides if they are "operably linked" to nucleotide sequences that encode polypeptides. An operable linkage is a linkage in which a regulatory DNA sequence and a DNA sequence to be expressed are connected in such a manner that gene expression as a peptide or antibody portion is possible in a recoverable amount. The exact properties of the regulatory region required for gene expression can vary from organism to organism, as is well known in similar techniques. See, for example, Sambrook et al., 2001 (above) and Ausubel et al., 1993 (above).

[0229] [000251] Accordingly, the present invention encompasses the expression of antibodies or peptides in either prokaryotic or eukaryotic cells. Suitable hosts include bacterial or eukaryotic hosts, including bacteria, yeast, insects, fungi, birds, and mammalian cells, in vivo or in situ, or in any host cell of mammalian, insect, bird, or yeast origin. Mammalian cells or tissues may be of human, primate, hamster, rabbit, rodent, cattle, pig, sheep, horse, goat, dog, or cat origin. Any other suitable mammalian cells known in the art may also be used.

[0230] [000252] In one embodiment, the nucleotide sequence of the present invention will be incorporated into a plasmid or viral vector capable of autonomous replication in a recipient host. Any of a wide variety of vectors can be used for this purpose. See, for example, Ausubel et al., 1993 (above). Important factors in the selection of a particular plasmid or viral vector include the ease with which recipient cells containing the vector can be recognized and selected from recipient cells that do not contain the vector; the desired number of copies of the vector in a particular host; and whether it is desirable that the vector can be "shuttle" between host cells of different species.

[0231] [000253] Examples of prokaryotic vectors known in the art include plasmids that can replicate within E. coli (e.g., pBR322, CoIE1, pSC101, pACYC184, .pi.vX, etc.). Such plasmids are disclosed, for example, by Maniatis et al., 1989 (above) and Ausubel et al., 1993 (above). Examples of Bacillus plasmids include pC194, pC221, and pT127. Such plasmids are disclosed by Gryczan in THE MOLEC. BIO. OF THE BACILLI 307-329 (Academic Press, NY, 1982). Suitable Streptomyces plasmids include Streptomyces bacteriophages such as p1J101 (Kendall et al., 169 J. Bacteriol. 4177-83 (1987)) and phLC31 (Chater et al., SIXTH INT'L SYMPOSIUM ON ACTINOMYCETALES BIO. 45-54 (Akademiai Kaido, Budapest, Hungary 1986)). Pseudomonas plasmids have been reviewed by John et al., 8 Rev. Infect. Dis. 693-704 (1986), lzaki, 33 Jpn. J. Bacteriol. 729-42 (1978), and Ausubel et al., 1993 (above).

[0232] [000254] Alternatively, useful gene expression elements for the expression of antibodies or peptides encoding cDNA include, but are not limited to, (a) viral transcription promoters and their enhancer elements such as the SV40 early promoter (Okayama et aI., 3 Mol. Cell. Biol. 280 (1983)), Rous sarcoma virus LTR (Gorman et aI., 79 Proc. Natl. Acad. Sci., USA 6777 (1982)), and Moloney mouse leukemia virus LTR (Grosschedl et aI., 41 Cell 885 (1985)), (b) splice regions and polyadenylation sites such as those derived from the late region of SV40 (Okayarea et aI., 1983), and (c) polyadenylation sites such as SV40 (Okayama et aI., 1983).

[0233] [000255] Immunoglobulin cDNA genes can be expressed as described by Weidle et al., Gene21 (1987) using the SV40 early promoter and its enhancer, the mouse immunoglobulin H chain promoter enhancer, the SV40 late region mRNA splicing, the rabbit S-globin intervention sequence, the immunoglobulin, the rabbit S-globin polyadenylation site, and the SV40 polyadenylation element as expression elements. In immunoglobulin genes consisting of a cDNA portion and a genomic DNA portion (Whittle et al., Protein Engine.499 (1987)), the transcription promoter may be human cytomegalovirus, the promoter enhancer may be cytomegalovirus and mouse / human immunoglobulin, and the mRNA splicing and polyadenylation region may be native chromosomal immunoglobulin sequences.

[0234] [000256] In one embodiment, in the expression of a cDNA gene in rodent cells, the transcription promoter is a viral LTR sequence, the transcription promoter enhancer is either or both a mouse immunoglobulin heavy chain enhancer and a viral LTR enhancer, the splice region contains an intron of more than 31 bp, and the polyadenylation and transcription termination regions are derived from the native chromosome sequence corresponding to the immunoglobulin chain being synthesized. In other embodiments, a cDNA sequence encoding another protein is combined with the expression elements listed above to achieve protein expression in mammalian cells.

[0235] [000257] Each fusion gene can be assembled into an expression vector or inserted into an expression vector. Recipient cells capable of expressing immunoglobulin chain gene products are then transfected with a peptide or H or L chain coding gene individually, or co-transfected with both H and L chain genes. The transfected recipient cells are cultured under conditions that enable the expression of the incorporated genes, and the expressed immunoglobulin chain or the antibody or fragment is recovered from the culture.

[0236] [000258] In one embodiment, a peptide or a fusion gene encoding H and L chains, or portions thereof, is then assembled into a separate expression vector used for co-transfection of recipient cells. Alternatively, fusion genes encoding H and L chains may be assembled on the same expression vector. Recipient cell lines for transfection of the expression vector and antibody production may be myeloma cells. Myeloma cells can synthesize, assemble, and secrete immunoglobulins encoded by the transfected immunoglobulin gene and have a mechanism for immunoglobulin glycosylation. Myeloma cells can be grown in culture or in the peritoneal cavity of mice, where secreted immunoglobulins may be obtained from ascites fluid. Other suitable recipient cells include lymphocytes such as B lymphocytes of bovine or non-bovine origin, hybridoma cells of bovine or non-bovine origin, or interspecies heterohybridoma cells.

[0237] [000259] Expression vectors carrying antibody constructs or polypeptides of the present invention can be introduced into suitable host cells by any of a variety of suitable means, including biochemical means such as transformation, transfection, conjugation, protoplast fusion, calcium phosphate precipitation, and application with polycations such as diethylaminoethyl (DEAE) dextran, as well as mechanical means such as electroporation, direct microinjection, and microprojectile bombardment. Johnston et al., 240 Science 1538 (1988).

[0238] [000260] Yeast may offer a substantial advantage over bacteria in the production of immunoglobulin H and L chains. Yeast performs post-translational peptide modifications, including glycosylation. Several recombinant DNA strategies currently exist that utilize potent promoter sequences and high copy number plasmids that can be used to produce desired proteins in yeast. Yeast recognizes the leader sequence of a cloned mammalian gene product and secretes a peptide (i.e., a pre-peptide) that carries the leader sequence. Hitzman et al., 11th Int'l Conference on Yeast, Genetics & Molec. Biol. (Montpelier, France, 1982).

[0239] [000261] Yeast gene expression systems can be routinely evaluated for the levels of production, secretion, and stability of peptides, antibodies, fragments, and their regions. One of a series of yeast gene expression systems incorporating promoters and termination elements from actively expressed genes encoding glycolytic enzymes, which are produced in large quantities when yeast is grown in glucose-rich media, may be used. Known glycolytic genes can also provide highly efficient transcriptional regulatory signals. For example, promoter and terminator signals of the phosphoglycerate kinase (PGK) gene may be used. Several approaches may be selected to evaluate the optimal expression plasmid for the expression of cloned immunoglobulin cDNA in yeast. See Vol. II DNA Cloning, 45-66, (Glover, ed.,) IRL Press, Oxford, UK 1985).

[0240] [000262] Bacterial strains may also be used as hosts for the production of antibody molecules or peptides described in the present invention. Plasmid vectors containing replicons and control sequences derived from species compatible with host cells are used in conjunction with these bacterial hosts. The vectors carry replication sites and specific genes capable of providing phenotypic selection in transformed cells. Several approaches may be selected for evaluating expression plasmids for the production of antibodies, fragments, and regions, or antibody chains encoded by cloned immunoglobulin cDNA in bacteria (see Glover, 1985 (above), Ausubel, 1993 (above), Sambrook, 2001 (above), Colligan et al., eds. Current Protocols in Immunology, John Wiley & Sons, NY, NY (1994-2001), Colligan et al., eds. Current Protocols in Protein Science, John Wiley & Sons, NY, NY (1997-2001)).

[0241] [000263] Host mammalian cells can be grown in vitro or in vivo. Mammalian cells provide post-translational modifications to immunoglobulin protein molecules, including leader peptide removal, hand L chain folding and assembly, antibody molecule glycosylation, and secretion of functional antibody proteins. Mammalian cells that may be useful as hosts for antibody protein production include fibroblast-derived cells such as Vero (ATCC CRL81) or CHO-K1 (ATCC CRL61) cells, in addition to the lymphoid-derived cells mentioned above. Many vector systems are available for the expression of cloned peptide hand L chain genes in mammalian cells (see Glover, 1985 (above)). Different approaches may be followed to obtain complete H2L2 antibodies. Co-expression of the hand L chain in the same cell is possible to achieve intracellular association and linkage of the hand L chain to the complete tetrameric H2L2 antibody and / or peptide. Co-expression can be performed using either the same or different plasmids in the same host. By placing the genes for both the H2L2 L chain and / or the peptide in the same plasmid and then transfecting cells with it, cells expressing both chains can be directly selected. Alternatively, cells can be first transfected with a plasmid encoding one chain, e.g., the L chain, and then the resulting cell line can be transfected with an H chain plasmid containing a second selectable marker. To generate cell lines with improved properties, such as higher production of assembled H2L2 antibody molecules or improved stability of the transfected cell line, cell lines that produce the peptide and / or H2L2 molecules via either pathway can be transfected with plasmids encoding additional copies of the peptide, H, L, or H-plus L chain, along with additional selectable markers.

[0242] [000264] Stable expression can be used for the long-term high yield generation of recombinant antibodies. For example, cell lines that stably express antibody molecules can be engineered. Rather than using an expression vector containing viral replication, host cells may be transformed with an immunoglobulin expression cassette and a selectable marker. Following the introduction of foreign DNA, the engineered cells may be grown in concentrated medium for 1-2 days, and then switched to selective medium. The selectable marker in the recombinant plasmid confers resistance to selection, allowing cells to stably incorporate the plasmid into their chromosomes and grow, thereby forming a focus that can be cloned and expanded into a cell line. Such engineered cell lines may be particularly useful in screening and evaluating compounds / components that directly or indirectly interact with antibody molecules.

[0243] [000265] Once the antibody of the present invention is generated, it can be purified by any method known in the art for the purification of immunoglobulin molecules, for example, by chromatography (e.g., ion exchange, affinity, particularly affinity for a specific antigen after protein A, and sizing column chromatography), centrifugation, absorptiometric differential solubility, or any other standard technique for the purification of proteins. In many embodiments, the antibody is secreted from cells into a culture medium and collected from the culture medium.

[0244] Pharmaceutical and veterinary uses [000266] The present invention also provides a pharmaceutical composition comprising the molecule of the present invention and one or more pharmaceutically acceptable carriers. More specifically, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an antibody or peptide according to the present invention as an active ingredient.

[0245] [000267] The “pharmaceutically acceptable carrier” includes any excipients that are nontoxic to cells or animals to which the drug is used at the dosage and concentration used. The pharmaceutical composition may include one or additional therapeutic agents.

[0246] [000268] "Pharmacologically acceptable" means a compound, material, composition, and / or dosage form that is suitable for contact with animal tissues within the bounds of sound medical judgment, without undue toxicity, irritation, allergic response, or complications of other problems commensurate with a reasonable benefit / risk ratio.

[0247] [000269] Examples of pharmaceutically acceptable carriers include solvents, dispersion media, buffers, coating agents, antimicrobial and antifungal agents, wetting agents, preservatives, buggers, chelating agents, antioxidants, isotonic agents, and absorption retarders.

[0248] [000270] Examples of pharmaceutically acceptable carriers include water; physiological saline; phosphate-buffered saline; dextrose; glycerol; alcohols such as ethanol and isopropanol; phosphates, citrates, and other organic acids; ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; EDTA; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®; isotonic agents such as sugars, polyhydric alcohols such as mannitol and sorbitol, and sodium chloride; and combinations thereof.

[0249] [000271] The pharmaceutical compositions of the present invention can be formulated in a variety of ways, including liquid, semi-solid, or solid dosage forms such as liquid solutions (e.g., injectable and injectable solutions), dispersions, or suspensions, liposomes, suppositories, tablets, pills, or powders. In some embodiments, the composition is in the form of an injectable or injectable solution. The composition may be in a form suitable for intravenous, intra-arterial, intramuscular, subcutaneous, parenteral, transmucosal, oral, topical, or transdermal administration. The composition may be formulated as an immediate-release, controlled-release, sustained-release, or delayed-release composition.

[0250] [000272] The compositions of the present invention may be administered either as individual therapeutic agents or in combination with other therapeutic agents. They may be administered alone, but generally they are administered with a pharmaceutical carrier selected based on a chosen route of administration and standard pharmaceutical practice. The antibodies disclosed herein may be administered orally or by topical administration of the antibodies (typically performed in a pharmaceutical formulation) to the airway surface by any preferred means, including parenteral injection (such as intraperitoneal, subcutaneous, or intramuscular injection). Topical administration to the airway surface may be performed by intranasal administration (e.g., by the use of a dropper, cotton swab, or inhaler). Topical administration of antibodies to the airway surface may also be performed by inhalation, such as by creating breathable particles of a pharmaceutical formulation (including both solid and liquid particles) containing the antibody as an aerosol suspension, and then having the subject inhale the breathable particles. Methods and apparatus for administering breathable particles of a pharmaceutical formulation are well known, and any conventional techniques may be used.

[0251] [000273] In some preferred embodiments, the antibody is administered by parenteral injection. For parenteral administration, the antibody or molecule may be formulated as a solution, suspension, emulsion, or lyophilized powder associated with a pharmaceutically acceptable parenteral vehicle. For example, the vehicle may be a solution of the antibody or its cocktail dissolved in an acceptable carrier such as an aqueous carrier, such as water, saline, Ringer's solution, dextrose solution, trehalose or sucrose solution, or 5% serum albumin, 0.4% saline, 0.3% glycine. Liposomes and non-aqueous vehicles such as non-volatile oils may also be used. These solutions are sterile and generally free of particulate matter. These compositions can be sterilized by conventional, well-known sterilization techniques. The compositions may contain pH adjusters and pharmaceutically acceptable auxiliary substances necessary to approximate physiological conditions, such as buffers and toxicity modifiers, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. The antibody concentration in these formulations can vary widely, for example, from less than about 0.5% by weight, typically from about 1% by weight or more to a maximum of 15% or 20% by weight, and will be selected according to the specific administration mode chosen, mainly based on fluid volume, viscosity, etc. The vehicle or lyophilized powder may contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulations are sterilized by commonly used techniques. Practical methods for preparing parenterally administered compositions are known or obvious to those skilled in the art and are described in detail, for example, in REMINGTON'S PHARMA.SCI. (15th ed., Mack Pub.Co., Easton, Pa., 1980).

[0252] [000274] The antibodies or molecules of the present invention may be lyophilized for storage and reconstituted in a suitable carrier before use. This technique has been shown to be effective for conventional immunoglobulins. Any suitable lyophilization and reconstitution technique may be used. Those skilled in the art will understand that lyophilization and reconstitution may result in varying degrees of antibody activity loss, which may need to be adjusted and offset by adjusting the usage level. Compositions containing these antibodies or cocktails thereof may be administered for the prevention of recurrence of pre-existing diseases and / or for therapeutic treatment. Suitable pharmaceutical carriers are described in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES, a standard reference text in the art. In therapeutic use, the composition is administered to a subject already suffering from the disease in an amount sufficient to cure, or at least partially halt or alleviate, the disease and its complications.

[0253] [000275] The effective dose of the composition of the present invention for the treatment of the conditions or diseases described herein will vary depending on many different factors, including, but not limited to, the pharmacodynamic characteristics of a particular drug and its mode and route of administration; the target site; the physiological state of the animal; other drugs administered; whether the treatment is prophylactic or therapeutic; the age, health, and weight of the recipient; the nature and degree of the type of symptoms; the type and frequency of concurrent treatments; and the desired effect.

[0254] [000276] The composition may be administered as a single or multiple doses at dose levels and in patterns selected by the treating veterinarian. In any case, the pharmaceutical formulation should provide an amount of the antibody of the present invention sufficient to effectively treat the subject.

[0255] [000277] The therapeutic dose may be titrated using routine methods known to those skilled in the art to optimize safety and efficacy.

[0256] [000278] The pharmaceutical composition of the present invention may contain a “therapeutic dose.” The “therapeutic dose” refers to the effective amount in the dosage and duration required to achieve the desired therapeutic outcome. The molecular amount of the therapeutic dose may vary depending on factors such as the disease state in the individual, age, sex, and weight, as well as the ability of the molecule to induce the desired response in the individual. The therapeutic dose is also the amount in which the therapeutically beneficial effect outweighs any toxic or adverse effects of the molecule.

[0257] [000279] In another embodiment, compositions of the present invention may be used, for example, to treat a variety of diseases and disorders in bovine animals. As used herein, the terms “treat” and “cure” refer to therapeutic measures, including preventive or mitigating measures, in which the subject is prevented or slowed (mitigated) of undesirable physiological changes associated with the disease or condition. Beneficial or desired clinical outcomes include, but are not limited to, symptom relief, reduction in the severity of the disease or condition, stabilization of the disease or condition (i.e., no worsening of the disease or condition), delay or slowing of the progression of the disease or condition, improvement or mitigation of the disease or condition, and remission (partial or complete) of the disease or condition, whether detectable or undetectable. Subjects requiring treatment include subjects already having the disease or condition, subjects prone to having the disease or condition, or subjects in which the disease or condition is to be prevented.

[0258] [000280] All patents and references cited herein are incorporated herein by reference in their entirety.

[0259] [000281] The following examples are provided to supplement the prior disclosure and to provide a better understanding of the subject matter described herein. These examples should not be considered limiting to the subject matter described herein. The examples and embodiments described herein are for illustrative purposes only, and it should be understood that various modifications or changes from therein will be obvious to those skilled in the art, fall within the true scope of the invention, and can be made without departing from the true scope of the invention. Examples [Examples]

[0260] Bovid IgG mutants method In vitro Fc receptor binding assay [000282] Recombinant bovid FcRn (bFcRn), FcgR1, FcgR2, FcgR3, and Fcg2R DNA were codon-optimized for mammalian expression and synthesized based on sequences from the NCBI database as shown in Table 1. The DNA was cloned into a pcDNA3.1(+) vector manipulated with a C-terminal 6×His+BAP tag (AGLNDIFEAQKIEWHE; SEQ ID NO: 113). All FcgRs were transfected into HEK293 or Expi-CHO cells (co-transfected with FcRn-α subunit and β-microglobulin), and the FcgR or FcRn complexes were purified by IMAC affinity purification via the c-terminal His tag.

[0261] [000283] The purified FcR was biotinylated as follows. The purified Fc receptor protein was dialyzed to 10 mM Tris-HCl, pH 8.0 and enriched using Amicon Ultra, 10KMWCO (EMD Millipore, Billerica, MA). The biotin acceptor peptide (BAP) AGLNDIFEAQKIEWHE (SEQ ID NO: 113), expressed at the c-terminus of the receptor, allowed biotin to be translocated to this range of amino acids using the biotin ligase BirA. The biotinylation reaction was carried out as described in the manufacturer's protocol (Avidity, LLC, Aurora, CO). The receptor was then dialyzed in PBS to remove residual biotin.

[0262] [000284] A Biacore SPR binding assay was designed to test the affinity of bovine IgG subclasses and mutants to bFcRn, bFcgR1, bFcgR2, bFcgR3, and bFcg2R. [Table 1]

[0263] Biacore method for bFcRn: 〔000285〕The binding affinity of bovine Fc-based antibodies or fusion proteins to bovine FcRn was determined by surface plasmon resonance (SPR). Using an SA sensor, all reported KDs were measured on a Biacore T200 (Cytiva, Marlborough, MA, USA). For the desired surface density, bovine FcRn was captured on the surface of the sensor. Running buffers of 20 mM MES, 150 mM NaCl, 0.005% Tween® 20, 0.5 mg / mL BSA, pH 6 and / or PBS, 0.0005% Tween® 20, pH 7.4 were used. Various concentrations of bovine CTLA4-Fc fusions or mAbs were titrated in the appropriate running buffer and flowed over the receptor surface. Regeneration was performed with 50 mM Tris-HCl, pH 8, 0.005% p20, and 0.5% BSA. Using the double-reference method, kinetic binding affinities were analyzed using Biacore T200 Evaluation software (Cytiva, Marlborough, MA, USA). The reference flow cell was subtracted from the flow cell containing immobilized bovine FcRn, and a blank experiment containing only buffer was subtracted from all experiments. The resulting curves were fitted to a 1:1 binding model. The experiments were performed at 25 °C.

[0264] Method for biotinylated bFcgR1, bFcgR2, and bFcgR3: [000286] A Biacore SPR binding assay was designed to test the affinity of bovine IgG subclasses for bFcgR1, bFcgR2, and bFcgR3. All reported KDs were measured at Biacore (Cytiva, Marlborough, MA, USA) using a Series S SA sensor. Biotinylated bovine FcgR1, R2, and R3 were captured on the sensor surface using a modified SA capture method to reach the desired surface density. 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% v / v surfactant P20, and pH 7.4 buffer were used as electrophoresis and titration buffers. Bovid CTLA4-Fc fusions or mAbs of various concentrations were titrated and flowed onto the receptor surface, and affinity was determined using Biacore T200 Evaluation software (Cytiva, Marlborough, MA, USA) with a 1:1 binding model. A double-reference method was applied, where a reference flow cell was subtracted from the flow cell containing the immobilized receptor, and a blank experiment containing only buffer was subtracted from all experiments. Flow cells were regenerated using 10 mM glycine, pH 1.5. Experiments were conducted at 15°C.

[0265] Methods for bFcg2R: Using the Series S CM5 sensor, all reported KDs were measured on a Biacore T200 (Cytiva, Marlborough, MA, USA). For the desired surface density, bovine Fcg2R was immobilized on the sensor surface using immobilization buffer by amine coupling (activation of carboxyl groups with an EDC-NGF mixture and inactivation of excess reactive groups with ethanolamine). A running buffer of 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% v / v surfactant P20, pH 7.4 buffer was used. Various concentrations of bovine CTLA4-Fc fusion or mAb were titrated, flowed over the receptor surface, and affinity was determined using Biacore T200 Evaluation software (Cytiva, Marlborough, MA, USA) with a 1:1 binding model. A double-reference method was applied where the reference flow cell was subtracted from the flow cell containing the immobilized receptor and a blank experiment containing only buffer was subtracted from all experiments. The flow cell was regenerated using 10 mM glycine, pH 1.5. Experiments were performed at 15 °C.

[0266] Regeneration of Fc fusion proteins and mAbs 〔000288〕Recombinant CTLA4-Fc fusions were constructed via insertion of the canine CTLA4 gene (NCBI NM_001003106.1) into pcDNA3.1(+) mammalian expression vectors containing bIgG1a (NCBI1S82409), bIgG2a (sequenced at Zoetis), bIgG3a (NCBI BTU63638) Fc starting immediately upstream of the heavy chain hinge region as shown in Figures 6, 14, and 18, respectively. Recombinant CTLA4-Fc fusions were also constructed for bIgG1b (X16701), bIgG2b (S82407), and / or bIgG3b (BTU63639) at the same Fc position as shown in Figures 6, 14, and 18. No additional linker was required.

[0267] [000289] Recombinant mAbs having the bIgG1a, bIgG1b, bIgG2a, bIgG2b, bIgG3a, and bIgG3b Fc regions were constructed by inserting a VH sequence upstream of and in frame with the nucleotide encoding the constant domain in a pcDNA3.1(+) mammalian expression vector. The constant region was one of the following: bIgG1a (NCBI 1S82409), bIgG1b (X16701), bIgG2a (sequencing by Zoetis), bIgG2b (S82407), bIgG3a (NCBI BTU63638), or bIgG3b (BTU63639). Similarly, the light chain was constructed by inserting a VL sequence upstream of and in frame with the constant region of the bovine kappa allele 1 (NCBI HQ213994.1).

[0268] [000290] Mutations were introduced into three wild-type subclasses in both CTLA4 Fc fusion and complete mAb formats to knock out binding to FcgR, knock out CDC and / or ADCP, improve stability, or increase affinity for bFcRn. For single-site targeted mutagenesis, mutations were incorporated at various locations on each wild-type plasmid using Agilent's QuikChange II Mutagenesis and related Agilent primer design tools (https: / / www.agilent.com / store / primerDesignProgram.jsp).

[0269] [000291] All CTLA4 fusion and mAb gene DNA were codon-optimized for mammalian expression, and the constructs were transiently expressed in HEK293 cells using FectoPRO® transfection reagents and protocol (Polyplus Transfection, New York, NY, USA), or in CHO cells using the ExpiCHO transient system (ThermoFisher Scientific) kit protocol. ExpiCHO expression was performed using either mAb or CTLA4 Fc fusion transfection, following the protocol outlined by ThermoFisher. For mAbs, a plasmid containing the gene sequence encoding the IgG kappa light chain was co-transfected with a plasmid encoding the IgG heavy chain. For HEK293 expression, equiweight heavy chain plasmids and kappa chain plasmids were co-transfected. For Fc fusions, a single plasmid was transfected. Cells were grown for 7 days (HEK293) or 12 days (CHO), after which the supernatant was collected for protein purification. CTLA4 Fc fusions and mAbs were screened for binding to protein A or protein G sensors via Octet QKe quantification (Pall ForteBio Corp, Menlo Park, CA, USA). Expression was quantified using Octet with protein A or protein G sensors using standard curves, and mAbs / fusion proteins were purified by protein G or protein A / G affinity chromatography. All protein constructs were eluted at pH 3.4 using sodium acetate pH 5.5 as the binding and washing buffer. The purified proteins were neutralized and dialyzed to 20 mM sodium acetate, pH 5.5, 140 mM NaCl for further analysis. The concentrations of mAbs and fusion proteins were measured via 280 nm NanoDrop. Protein quality was evaluated using analytical SEC and standard Coomassie protein gels.

[0270] [000292] Table 2 lists the CTLA4 Fc fusions generated for three bovine IgG wild-type subclasses and mutations. Mutations were also made to mAbs at the same positions, as shown in Table 2.

[0271] [000293] Additional mutations introduced into bovine IgG but not into Fc fusions include a "DP" stabilizing mutant of bIgG1a, a mutation that increases affinity for bFcRn, and R433H on bIgG3a. [Table 2-1] [Table 2-2]

[0272] Table 3 below describes the mutations performed on bIgG1b, IgG2b, and IgG3b, including changes in amino acids resulting from nucleotide mutations. Table 3 also shows the adjacent sequences to the mutations. The same Fc mutations in Table 3 were performed on bIgG1a, bIgG2a, and IgG3a, and the mutations resulted in identical amino acid sequences for the a and b allotypes. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Examples]

[0273] bIgG mutations knock out effector function. [000294] Several mutations were introduced into the Fc region of the bIgG1a allotype to knock out effector functions: 1) binding of bIgG1a to bFcgR1, bFcgR2, and bFcgR3, 2) complement-killing activity (CDC) in cell-based assays, and 3) phagocytosis in ADCP cell-based assays.

[0274] [000295] The "Winter" (or "Win") region is located immediately downstream of the hinge, as previously reported for human IgG1. This LLGG "Winter" region in human IgG1 is species-specific. For bovine IgG1, it is LPGG (Figure 2). In human IgG1, the mutation commonly referred to as "LALA" is located in Leu234Ala and Leu235Ala. For bovine IgG1, the corresponding Winter mutations are Leu234Ala and Pro235Ala, but an additional residue is also mutated. This additional mutation is Gly237Ala (numbered according to the Eu index in Kabat).

[0275] [000296] The "PAP to SAS" (Pro329Ser_Pro331Ser) and "PAP to SAP" (Pro329Ser) mutations on bIgG1a were devised based on bIgG2 because bIgG2 does not induce complement activity in cell-based assays. Bovid IgG2a has a naturally occurring SAS site in CH2, whereas bIgG1a is PAP in this region, as shown in Figure 2. Therefore, it was hypothesized that mutating PAP in bIgG1a to either SAS or SAP would eliminate CDC.

[0276] 〔000297〕The "SS" mutation on bIgG1a (Ala330Ser, Pro331Ser), where the hIgG4 subclass has a weak affinity for FcgR and thus has negligible effector function, is based on a mutation in human IgG1 similar to human IgG4 in this same region, from PAP to PSS. Indeed, the "SS" mutation on hIgG1 knocks out effector function. Since bovine IgG1 has the same PAP sequence as hIgG1 in this region, it was hypothesized that the mutation from PAP to PSS on bIgG1 would knock out ADCC, ADCP, CDC, and FcgR binding. The SS mutation was added to the Winter mutation on bIgG1.

[0277] 〔000298〕The above mutations were introduced onto bIgG1a Fc: only the Winter mutation, L234A_P235A_G237A "Win" (SEQ ID NO: 16), Winter mutation + SS mutation, L234A_P235A_G237A_A330S_P331S "WinSS" (SEQ ID NO: 18), Winter mutation + SAS mutation, L234A_P235A_G237A_P329S_P331S "WinSAS" (SEQ ID NO: 17), only the SAS mutation, P329S_P331S "SAS" (SEQ ID NO: 15), and only the SAP mutation, P329S "SAP" (SEQ ID NO: 14). These mutations were aligned in Figure 6.

[0278] [000299] The binding affinity of the above mutations to the Fcγ receptor was compared to that of bIgG1a wild type. The mutants were also tested in functional cell-based assays, and the data show that both SAS and SAP mutations dramatically reduce CDC activity. SAS and SAP mutations also completely knock out ADCP. Unexpectedly, the "Winter" mutation appeared to enhance rather than reduce complement activity in cell-based CDC assays and has a negligible effect on ADCP in cell-based assays. Also unexpectedly, the "SS" mutation on bIgG1a does not completely knock out binding to bFcgR1 and bFcgR2. The SS mutation on bIgG1 has only a slight reduction on CDC and only partially knocks down ADCP in cell-based assays. [Examples]

[0279] Effect of bIgG Fc mutations on Fc receptor binding affinity in bovine animals [000300] The ability to knock out binding to the bovine Fcγ receptor was evaluated by comparing the SPR Biacore bFcgR affinity of bIgG1a and bIgG1b wild-type Fc with the bIgG1a and bIgG1b mutations described above. Figure 6 shows the constant region alignment of the bIgG1a wild-type recombinant mAb with five Fc mutants. Figure 3 shows the alignment of the bIgG1a allotype with the bIgG1b allotype. All mutations performed on bIgG1 are identical to the a and b allotypes. The Biacore method was performed for bFcgR1, R2, and R3 as described in Example 1.

[0280] [000301] Table 4 shows the results of effector function Fc mutations on bIgG1a and bIgG1b binding to the Fcγ receptor. For bIgG1 wild type, the two allotypes have similar binding affinities to bFcgR1, bFcgR2, and bFcgR3. The Winter mutation (bIgG1aWin) knocked out binding to bFcgR3 but did not significantly affect the affinity for bFcgR1 or bFcgR2. Adding the SS mutation to Winter (bIgG1aWinSS) reduced binding to bFcgR1 and bFcgR2 somewhat, while maintaining negligible binding to bFcgR3. Binding to all three Fcγ receptors was knocked out only when SAS was added to the Winter mutation (bIgG1aWinSAS), the SAS mutation alone (bIgG1aSAS), or the SAP mutation alone (bIgG1aSAP). The bovine bFcgR1 has very weak binding to IgG1aSAP and is therefore effectively knocked out. With two exceptions, Table 4 shows that the bIgG1b wild-type and bIgG1b mutant had similar binding affinities to the bIgG1a wild-type and bIgG1a mutant, respectively. Thus, the two allotypes are quite comparable, except for 1) WinSS on bFcgR2 and 2) SAP on bFcgR1, but the KD of both these mutants is significantly lower than that of the wild-type. [Table 4]

[0281] CDC assay [000302] A CDC cell-based assay was developed and used to characterize the efficacy of five CTLA4 bovine IgG1a Fc fusion proteins (Figure 6) in CDC-mediated activity and to define key residues in the Fc region that determine the CDC activity of bovine IgG subtypes. This assay utilizes CHO target cells engineered to express canine CD80 that binds to CTLA4 on the Fc fusion protein. These target cells have been used in previous canine ADCC assays and are used in the CDC assay due to their reliability.

[0282] [000303] Incubation of fusion protein-bound target cells with complement-preserved serum can result in Fc binding on the fusion protein, which can capture the component C1q initiating the complement cascade and ultimately forming a membrane attack complex. The pore-forming complex mediates cell lysis of the target cell, measured by loss of cell viability. Without Fc binding to C1q, there is no resulting cell lysis / death.

[0283] [000304] Briefly, CD80-expressing CHO cells (target cells) were plated at 40,000 cells / well in CD CHO medium in a round-bottom 96-well plate. The titrated fusion protein in CD CHO medium was added to the target cells and conjugated at 37°C for 60 minutes. Bovidian complement-preserved serum (30% in CD CHO medium) was added to the plate at 37°C for 45 minutes. Cell viability was then measured using CellTiter-Glo, and the data were expressed as "control cell viability %" calculated using a control without fusion protein + complement-preserved serum control.

[0284] [000305] As shown in Figure 7 and Table 5, the Win mutation alone does not knock out the CDC activity of bIgG1a or bIgG1b Fc. It appears to enhance CDC activity. The WinSS mutation induces CDC, albeit very weakly. The WinSAS, SAS alone, and SAP mutations significantly reduce or completely knock out CDC activity for both bIgG1a Fc and bIgG1b Fc.

[0285] In silico modeling [000306] The FAb sequences of bovine antibodies were concatenated to the Fc domain sequences of various bovine skeletal subclasses using their respective hinge regions. The antibody homology modeling function of the Molecular Operating Environment 2019.0102 program (MOE2019.0102), developed by Chemical Computing Group, was implemented to model the 3D structures of wild-type (WT) and mutant constructs for each bovine skeletal allotype. MOE2019.0102 provides a flexible and automated graphical user interface for antibody homology modeling, and default parameters were selected for the modeling experiments.

[0286] [000307] To model the mAb structure, a knowledge-based approach was employed using the embedded PDB database of MOE2019.0102. A sequence-to-profile alignment algorithm was used to rank heavy and light chain sequence templates using a scoring algorithm, with scores above 85% ensuring the selection of antibody templates with physically realistic structures. Once the CDR and loop templates were coupled, the model was then optimized using the same pipeline. The structural stability of the model was validated using a Ramachandran plot to check the stereochemical quality of the protein structure.

[0287] [000308] To understand the structure-activity relationship across the mutated constructs, the method described above was applied to bIgG1a_WINSAS, bIgG1b_WINSAS, bIgG1c_WINSAS, and bIgG1d_WINSAS. The structures were superimposed, and the mutated residues were indicated by arrows (Figure 8A). RMSD plots were generated to calculate the mean squared deviation of the four structures relative to each other (Figure 8B). RMSD values ​​of 2.0 Å or less are considered standard for considering two structures to be identical. The results showed that the _bIgG1a_WINSAS construct was identical to its other allotype counterpart, bIgG1b_WINSAS, as its RMSD was 1.24. This was also supported in the CDC assay (Figure 7), in which bIgG1a_WINSAS showed the same loss of CDC activity as bIgG1b_WINSAS. This provides further support for demonstrating that the antibody models generated by the method described above provide an accurate representation of the bovine skeletal structure. Furthermore, when comparing the antibody models of bIgG1a_WINSAS and bIgG1b_WINSAS with those of bIgG1c_WINSAS and bIgG1d_WINSAS, the RMSD values ​​were in the range of 0.94 to 1.24 Å. Therefore, it is highly reliable to predict that bIgG1c_WINSAS and bIgG1d_WINSAS will exhibit similar functional activity deficiencies (CDC, ADCP, and ADCC) as bIgG1a_WINSAS.

[0288] ADCP FET [000309] The ADCP cell-based assay was developed and used to characterize the efficacy of five CTLA4 bovine IgG1a Fc fusion proteins (Figure 6) in mediating ADCP and to define key residues in the Fc region that determine the ADCP activity of bovine IgG subtypes. This assay utilizes CHO target cells engineered to express canine CD80 that binds to canine CTLA4 on the Fc fusion protein. These target cells have been used in previous canine ADCC assays and are used in the CDC assay due to their reliability.

[0289] [000310] For this assay, incubation of the Fc fusion protein / target cell complex with bovine alveolar macrophages can result in Fc binding to the Fcγ receptor on the macrophage, cross-linking between the CHO target cell and the macrophage effector, and thereby initiation of phagocytosis of the target cell. ADCP is measured by the signal intensity and frequency of a pH-sensitive fluorescent dye within a population of effector macrophages in co-culture, and the fluorescent cells indicate effectors that have successfully internalized the target cell into acidic lysosomes.

[0290] [000311] Briefly, canid CD80-expressing CHO cells (CD80 target cells) or non-CD80-expressing parental CHO cells (parental target cells) were pre-stained with pHrodo red dye at 37°C for 30 minutes. The cells were then incubated with CTLA4-Fc fusion protein for 20 minutes to mediate CTLA4:CD80 binding, and subsequently co-cultured with pre-plated adherent bovine alveolar macrophages stained with a cell marker (CellTrace Violet, CTV) to aid in subsequent identification. 60,000 target cells were plated with 30,000 effector macrophages in a 96-well plate. The cells were then co-cultured for 6 hours, removed from the plate, and analyzed by flow cytometry to identify effector cells (CTV+) that had successfully undergone ADCP (pHrodo+). As shown in Figure 9 and Table 5, wild-type bIgG1a is a potent activator of ADCP in bovine alveolar macrophages. The bIgG1aWin mutation alone does not significantly affect the ADCP activity of bIgG1a Fc and may slightly enhance ADCP, as seen with CDC activity. The WinSS mutation partially knocks down ADCP, while WinSAS, SAS alone, and SAP mutations on bIgG1a completely suppress ADCP function.

[0291] [000312] Incubation of wild-type bIgG1a with target cells that do not express canid CD80 (IgG1 parent) also did not induce ADCP, indicating that the observed target cell internalization requires specific activity of the fusion protein and is not mediated by alternative mechanisms.

[0292] [000313] Phagocytosis (ADCP) is mediated by multiple human Fcγ receptors, including FcgR1, and DNA sequence analysis shows that the motif of the IgG-binding domain of bovine FcgR1 is highly conserved compared to its human and mouse counterparts. The cell-based ADCP data in Figure 9 and Table 5 are comparable to the binding affinities of bIgG1a and mutants to bFcgR1 in Table 4. The Winter mutation (bIgG1aWin) did not significantly affect bFcgR1 affinity. Adding the SS mutation to Winter (bIgG1aWinSS) knocked down binding to bFcgR1 to some extent, but did not completely knock out binding. Binding to bFcgR1 was knocked out only when SAS was added to the Winter mutation (bIgG1aWinSAS), the SAS mutation alone (bIgG1aSAS), or the SAP mutation alone (bIgG1aSAP). The bovine gene bFcgR1 has only negligible binding to IgG1aSAP and is therefore effectively knocked out. [Table 5] [Examples]

[0293] bIgG DP mutation for stabilization [000314] In an analytical investigation of the natural wild-type subclass of bovine IgG1a, low molecular weight species (LMWS) were observed by size exclusion chromatography (SEC), as shown in Figure 10. To investigate possible causes, samples were subjected to mass spectrometry, which identified two clipping sites located in the constant heavy chain of bovine IgG1a between D216 and P217, and between D270 and P271. These two chemical cleavage sites are present in the natural amino acid sequence of bovine IgG1a Fc (NCBI reference 1S82409). Elimination of cleavage / clipping sites in the constant domain of bIgG1a is desirable to increase the conformational stability, the proportion of intact monomers, and the overall developability of the bovine IgG1 subclass. Mutations were made in the constant domain of bovine IgG1a to eliminate these cleavage / clipping sites (Table 6). These identified cleavage sites depend on amino acid sequences that can induce non-enzymatic disruption of the binding between Asp(D) and Pro(P) amino acids in IgG proteins. While intentional cleavage of DP binding is well described in the literature using acids and heat, not all DP sites are structurally accessible and do not cleave even at high temperatures or short-term exposure to acid. Therefore, it is unclear whether the tendency of these sequence sites automatically leads to clipping of bIgG1a Fc. [Table 6]

[0294] [000315] The above-mentioned mutation from DP to EP was constructed via rapid mutational mutagenesis of a mammalian expression vector containing bIgG1a. Monoclonal antibody (mAb) variants were expressed in the mammalian suspension cell line EXPICHO-S (Chinese hamster ovary) cells obtained from Thermo Fisher. The suspension EXPICHO-S cells were maintained in EXPICHO expression medium (Gibco) at 0.14–8.0 × 10 e6 cells / ml. The cells were diluted on day 1 and on the transfection day according to the ExpiCHO protocol user manual. The diluted cells were transfected using reagents supplied from the ExpiFectamine CHO transfection kit (Gibco) under Max Titer conditions as described in the protocol. After incubation for 12–14 days, the cultures were harvested and clarified. The conditional medium was loaded onto MabSelect Sure LX (GE Healthcare) which had been pre-equilibrated in PBS. After loading the sample, the resin was washed with PBS, then with 20 mM sodium acetate, pH 5.5. The sample was eluted from the column with 20 mM acetic acid, pH 3.5. After elution, a pool was prepared and neutralized to 4% by adding 1 M sodium acetate. Depending on the available quantity and intended use, the sample was sometimes replaced with a final buffer (e.g., PBS, etc.). The concentration was measured by absorbance at 280 nm.

[0295] [000316] Analytical SEC was performed using a TOSOH BioScience TSK Gel Super SW3000, 4.6 mm, 10 x 30 cm, 4 μm column at a flow rate of 0.25 ml / min in 200 mM NaPhosphate pH 7.2 electrophoresis buffer.

[0296] [000317] Mass spectrometry was performed on wild-type natural bovine IgG1a and mutants. Samples were deglycosylated using PNGase F (New England Biolabs) and reduced with DTT (Thermo). Samples were analyzed using a maXis+ESI instrument (Bruker). Figure 10 confirms that the mass of the identified DP clip site is evident in the natural bIgG1a heavy chain. The bIgG1a double mutants D216E (site 1) and D270E (site 2) were also analyzed by mass spectrometry in the same manner as natural Fc. From this data, it is clear that the DP clip is no longer present.

[0297] [000318] The introduced DP-to-EP mutation (Figure 12) removed the cleavage / clip site from bIgG1a Fc, as demonstrated by mass spectrometry (Figure 11). Removal of these cleavage sites can improve the homogeneity, as-is IgG purity, and overall development potential of this subclass for therapeutic applications.

[0298] In silico modeling [000319] The methods described above for bIgG1a_WINSAS, bIgG1b_WINSAS, bIgG1c_WINSAS, and bIgG1d_WINSAS were applied to the bIgG1DP1_DP2 allotype. The results shown in Figure 13 indicate that the bov_G1a_DP1_DP2 construct was identical to the other allotype counterparts, bIgG1b_DP1_DP2, bIgG1c_DP1_DP2, and bIgG1d_DP1_DP2, with RMSD values ​​ranging from 0.76 to 1.14 Å. Therefore, based on both experimental and model results, we can predict with high certainty that DP1_DP2 variants in allotypes bIgG1b, bIgG1c, and bIgG1d function in a similar manner to bIgG1a_DP1_DP2. [Examples]

[0299] bIgG mutations knock out effector function. [000320] Several mutations were introduced into the Fc region of the bIgG2a allotype to knock out effector function: 1) bIgG2a's binding to the only Fcγ receptor it engages with, bFcg2R, and 2) its phagocytosis in ADCP cell-based assays, or reduced to a negligible degree.

[0300] [000321] HDX epitope mapping of bovine IgG2a to bFcg2R revealed discontinuous epitopes on bIgG2a. In a campaign to eliminate or reduce binding to bFcg2R to a negligible degree, an alanine mutation panel was constructed for this region of bIgG2a. Mutations that were effective in dramatically knocking down Fcγ receptor binding while maintaining neonatal Fc receptor affinity are shown in Figure 14. These mutations are L432A, N434A, and M437A. In addition, the following combinations of L432A, N434A, and M437A successfully knocked out binding to bFcg2R: L432A_N434A, L432A_M437A, N434A_M437A, and L432A_N434A_M437A. [Examples]

[0301] Effects of bIgG alanine mutations on bFcg2R and bFcRn binding affinity [000322] The ability to knock out binding to bFcg2R while maintaining affinity for bFcRn was evaluated by comparing the SPR Biacore affinity difference between the bIgG2a wild-type Fc and the bIgG2a alanine mutant described above. Figure 14 shows the constant region alignment of the bIgG2a wild-type (wt) recombinant mAb with seven Fc mutants. Figure 4 shows the alignment of the bIgG2a allotype with the bIgG2b allotype. All mutations performed on bIgG2 are identical to the a and b allotypes. bIgG2a wt and mutants were produced as mAbs and their binding affinity to the bovine Fcγ receptor and the bovine neonatal Fc receptor was experimentally tested using Biacore. The Biacore methods for bFcg2R, bFcRn, bFcgR1, bFcgR2, and bFcgR3 were performed as described in the Examples section above.

[0302] [000323] As shown in Table 7, three single point mutations on bIgG2a, L432A, N434A, and M437A dramatically knock down binding to bFcg2R, resulting in almost complete knockout of binding. The double mutation L432A_N434A reduces binding to bFcg2R fourfold compared to wild-type binding. The double mutations L432A_M437A, N434A_M437A, and the triple mutation L432A_N434A_M437A completely knock out binding to Fcg2R compared to wild-type Fc.

[0303] [000324] Bovid Fcg2R knockout mutations had varying effects on binding to bovid FcRn. IgG recycling by pH-dependent FcRn requires strong affinity at pH 6 to avoid endosomal degradation and weak affinity at pH 7.4 to return rescued IgG to circulation. Three single point mutations had the least effect on bFcRn binding at pH 6 and maintained strong affinity similar to the wild type, while double and triple mutations had the greatest effect on bFcRn affinity at pH 7.4, reducing affinity below the detection limit. [Table 7]

[0304] [000325] bIgG2a wild-type and all bIgG2a Fcg2R knockout mutations either did not bind to bFcgR1, bFcgR2, and bFcgR3, or the binding was negligible, as shown in Table 8. [Table 8]

[0305] [000326] In addition to the mAb reagents for bIgG2a wild-type and mutants shown in Tables 7 and 8, CTLA4-Fc fusion versions for both bIgG2a and b allotype were prepared as described above. Investigation of bFcg2R affinity between the wild-type bIgG2a allotype CTLA4-Fc fusion and the wild-type bIgG2b allotype CTLA4-Fc fusion showed nearly identical KD values, 4.17E-08 vs. 3.14E-08 (Table 9). Comparison of the two allotypes for all Fc mutations also showed very similar bFcg2R binding affinities. [Table 9]

[0306] CDC assay [000327] A CDC cell-based assay was developed and used to characterize the efficacy of seven CTLA4 bovine IgG2a Fc fusion proteins (Figure 14) in CDC-mediated activity and to define key residues in the Fc region that determine the CDC activity of bovine IgG subtypes. This assay utilizes CHO target cells engineered to express canine CD80 that binds to CTLA4 on the Fc fusion protein. These target cells have been used in previous canine ADCC assays and are used in the CDC assay due to their reliability. The assay method was carried out as described above for the bIgG2a CTLA4 Fc fusion.

[0307] [000328] As shown in Figure 15 and Table 10, neither of the two bovine IgG2 wild-type allotypes, bIgG2a and bIgG2b, induced CDC in the cell-based assay, while the positive control bIgG1a had the same CDC activity as in the previous experiment. In addition, none of the seven alanine mutations altered bIgG1a CDC function.

[0308] In silico modeling: [000329] The methods described above for bIgG1a_WINSAS, bIgG1b_WINSAS, bIgG1c_WINSAS, and bIgG1d_WINSAS were applied to bIgG2a variants. In this subclass, no RMSD changes greater than 2 Å were observed, indicating that the two allotypes fold similarly (Figure 16B). Similar to the previous subclass, if having all possible mutations in a single construct (L432, N434A, and M437A) does not result in significant changes in protein folding, then individual mutations should also not affect the protein model. These models are also supported by effector function data observed using CDC assays. These antibody models, along with the SPR binding data (i.e., experimental data) in Table 7, demonstrate that bIgG2a_L432A_N434A_M437A, bIgG2b_L432A_N434A_M437A, and various combinations of these mutations (listed in Tables 2 and 7) fold and bind in the same manner and therefore will have similar ADCP and ADCC effector deficiencies.

[0309] ADCP FET [000330] The ADCP cell-based assay was developed and used to characterize the efficacy of seven CTLA4 bovine IgG2a Fc fusion proteins (Figure 14) in ADCP-mediated activity and to define key residues in the Fc region that determine the ADCP activity of bovine IgG subtypes. This assay utilizes CHO target cells engineered to express canine CD80 that binds to CTLA4 on the Fc fusion protein. These target cells have been used in previous canine ADCC assays and were used in the CDC assay due to their reliability.

[0310] [000331] For this assay, incubation of the Fc fusion protein / target cell complex with bovine alveolar macrophages can result in Fc binding to the Fcγ receptor on the macrophage, cross-linking of the CHO target cell with the macrophage effector, and thereby initiation of phagocytosis of the target cell. ADCP is measured by the signal intensity and frequency of a pH-sensitive fluorescent dye within a population of effector macrophages in co-culture, and the fluorescent cells indicate effectors that have successfully internalized the target cell into acidic lysosomes.

[0311] [000332] Briefly, canid CD80-expressing CHO cells (CD80 target cells) or non-CD80-expressing parental CHO cells (parental target cells) are pre-stained with pHrodo red dye at 37°C for 30 minutes. The cells are then incubated with CTLA4-Fc fusion protein for 20 minutes to mediate CTLA4:CD80 binding, and subsequently co-cultured with pre-plated adherent bovine alveolar macrophages stained with a cell marker (CellTrace Violet, CTV) to aid in subsequent identification. 60,000 target cells are plated in a 96-well plate with 30,000 effector macrophages. The cells are co-cultured for 6 hours, then removed from the plate and analyzed by flow cytometry to identify effector cells (CTV+) that have undergone successful ADCP (pHrodo+).

[0312] [000333] As shown in Figure 17 and Table 10, the bovine IgG2 subclass is not as potent in activating ADCP in bovine alveolar macrophages as the bovine IgG1 subclass (see Figure 9 and Table 5), but bIgG2 can induce ADCP at higher concentrations. All bIgG2a alanine mutations eliminate the ADCP activity of wild-type bIgG2a. [Table 10] [Examples]

[0313] bIgG mutations knock out effector function. [000334] Several mutations were introduced into the Fc region of the bIgG3a allotype to knock out effector functions: 1) binding of bIgG3a to bFcgR1, bFcgR2, and bFcgR3, 2) complement-killing activity (CDC) in cell-based assays, and 3) phagocytosis in ADCP cell-based assays.

[0314] [000335] The "Winter" (or "Win") region is located immediately downstream of the hinge, as described above for human IgG1. This LLGG "Winter" region of human IgG1 differs by species. For bovine IgG3, it is PLGG (Figure 2). As discussed above, the mutation commonly referred to as "LALA" in human IgG1 is located in Leu234Ala and Leu235Ala.

[0315] [000336] For bIgG3, the corresponding Winter mutations are Pro234Ala and Leu235Ala, but an additional residue is also mutated. This additional mutation is Gly237Ala (numbered according to the Eu index in Kabat).

[0316] [000337] The "PAP to SAS" (Pro329Ser, Pro331Ser) and "PAP to SAP" (Pro329Ser) mutations on bIgG3a were devised based on bIgG2. Bovid IgG2 does not induce complement activity in cell-based assays. Bovid IgG2a has a naturally occurring SAS site in CH2, whereas bIgG3a is PAP in this region, as shown in Figure 2. Therefore, it was hypothesized that mutating PAP in bIgG3a to either SAS or SAP would eliminate CDC.

[0317] [000338] The above mutations were introduced onto bIgG3a Fc: Winter mutation only, P234A_L235A_G237A "Win" (SEQ ID NO: 29); Winter mutation + SAS mutation, P234A_L235A_G237A_P329S_P331S "WinSAS" (SEQ ID NO: 30); SAS mutation only, P329S_P331S "SAS" (SEQ ID NO: 28); and SAP mutation only, P329S "SAP" (SEQ ID NO: 27). These mutations are aligned in Figure 18 and numbered according to the Eu index in Kabat.

[0318] [000339] The binding affinity of the above mutations to the Fcγ receptor was compared to that of bIgG3a wild type. The mutants were also tested in functional cell-based assays, and the data showed that only the Win mutation slightly attenuated CDC, while the WinSAS, SAS only, and SAP only mutations completely knocked out CDC activity. All four mutations—Win, WinSAS, SAS, and SAP—completely knocked out ADCP function. [Examples]

[0319] Effect of bIgG Fc mutations on Fc receptor binding affinity in bovine animals [000340] The ability to knock out binding to the bovine Fcγ receptor was evaluated by comparing the SPR Biacore bFcgR affinity of bIgG3a and bIgG3b wild-type Fc with the bIgG3a and bIgG3b mutations described above. Figure 18 shows the constant region alignment of the bIgG3a wild-type recombinant mAb with four Fc mutants. Figure 5 shows the alignment of the bIgG3a allotype with the bIgG3b allotype. All mutations performed on bIgG3 are identical to the a and b allotypes.

[0320] [000341] As described in the above examples, the Biacore method was performed for bFcgR1, R2, and R3. Table 11 shows the results for effector function bIgG3a and bIgG3b Fc mutations for binding to the Fcγ receptor. For bIgG3 wild type, the two allotypes have similar binding affinity to bFcgR1, 9.36E-09 compared to 1.25E-08. The two allotypes have different KDs for bFcgR2 and bFcgR3, but both wild-type allotypes bind. All mutations for both a and b allotypes, bIgG3Win, bIgG3WinSAS, bIgG3SAS, and bIgG3SAP, knocked down binding to bFcgR1, bFcgR2, and bFcgR3 to negligible affinity. Thus, the two allotypes are comparable in terms of knocking out receptor binding. [Table 11]

[0321] CDC assay [000342] A CDC cell-based assay was developed and used to characterize the efficacy of four CTLA4 bovine IgG3a Fc fusion proteins (Figure 18) in CDC-mediated activity and to define key residues in the Fc region that determine the CDC activity of bovine IgG subtypes. This assay utilizes CHO target cells engineered to express canine CD80 that binds to CTLA4 on the Fc fusion protein. These target cells have been used in previous canine ADCC assays and were utilized in the CDC assay due to their reliability.

[0322] [000343] For the bIgG3a CTLA4 Fc fusion, the assay method was carried out as described in the above examples.

[0323] [000344] As shown in Figure 19 and Table 12, bIgG3a wild-type Fc and bIgG3b wild-type Fc showed slightly weaker CDC activity than bIgG1a wild-type Fc. The Win mutation itself does not knock out the CDC activity of bIgG3a Fc or bIgG3b Fc. Mutations in Win-SAS, SAS only, or SAP only all completely knock out CDC activity.

[0324] In silico modeling [000345] Similar to subclass IgG1, the effects of WINSAS mutations in bovid subclass 3 were studied using the same methodology and superimposed using the same protocol (Figure 20A). As shown in Figure 19, WINSAS mutations in both bIgG3a and bIgG3b completely suppressed CDC function. In silico modeling data showed that the two allotypes, bIgG3a_WINSAS and bIgG3b_WINSAS, have an RMSD of 1.16 Å and are therefore expected to have similar protein folding (Figure 20B). The binding data listed in Table 11 and the in silico modeling data in Figure 20 show that bIgG3a_WINSAS and bIgG_3b fold and bind in the same manner, and therefore, based on both experimental and modeling results, we can predict with high certainty that, in addition to CDC function, the bIgG3b_WINSAS construct also suppresses ADCP and ADCC function similar to that of bIgG3a_WINSAS.

[0325] ADCP FET [000346] ADCP cell-based assays were developed and used to characterize the efficacy of four CTLA4 bovine IgG3a Fc fusion proteins (Figure 18) in mediating ADCP and to define key residues in the Fc region that determine the ADCP activity of bovine IgG subtypes. This assay utilizes CHO target cells engineered to express canine CD80 that binds to CTLA4 on the Fc fusion protein.

[0326] [000347] For this assay, incubation of the Fc fusion protein / target cell complex with bovine alveolar macrophages can result in Fc binding to the Fcγ receptor on the macrophage, cross-linking between the CHO target cell and the macrophage effector, and thereby initiation of phagocytosis of the target cell. ADCP is measured by the signal intensity and frequency of a pH-sensitive fluorescent dye within a population of effector macrophages in co-culture, and the fluorescent cells indicate effectors that have successfully internalized the target cell into acidic lysosomes.

[0327] [000348] Briefly, canid CD80-expressing CHO cells (CD80 target cells) or non-CD80-expressing parental CHO cells (parental target cells) are pre-stained with pHrodo red dye at 37°C for 30 minutes. The cells are then incubated with CTLA4-Fc fusion protein for 20 minutes to mediate CTLA4:CD80 binding, and subsequently co-cultured with pre-plated adherent bovine alveolar macrophages stained with a cell marker (CellTrace Violet, CTV) to aid in subsequent identification. 60,000 target cells are plated in a 96-well plate with 30,000 effector macrophages. The cells are co-cultured for 6 hours, then removed from the plate and analyzed by flow cytometry to identify effector cells (CTV+) that have undergone successful ADCP (pHrodo+).

[0328] [000349] As shown in Figure 21 and Table 12, wild-type bIgG3a is a potent activator of ADCP in bovine alveolar macrophages. Mutations in bIgG3aWin alone, WinSAS, SAS alone, and SAP alone all eliminate ADCP function.

[0329] [000350] Notably, while the Win mutation in bIgG3a exhibits some trace activity at peak concentrations, this mutation has little effect in driving ADCP, in contrast to its activity in both bIgG1a ADCP and bIgG3a CDC. This may indicate that bIgG3a ADCP activity is mediated only via a subset of bFcgRs in alveolar macrophages that require binding of the Winter site mutation, whereas bIgG1a mediates ADCP via a distinct bFcgR that does not require binding of the Winter site in these cells. Variable utilization of FcgRs may also explain the different observed EC50 of wild-type bIgG1a compared to bIgG3a. Conversely, the different secondary structures between bIgG1a and bIgG3a may result in the differential utilization of the Winter site in binding to the appropriate receptor that drives ADCP. [Table 12] [Examples]

[0330] bIgG mutations improve FcRn affinity [000351] As shown in Table 13, bovine IgG3a has a weaker binding affinity to bFcRn at pH 6 compared to bIgG2a. Unexpectedly, bIgG2a has a 10-fold higher affinity than bIgG1a and bIgG3a, but bIgG2a binding to bovine FcRn at pH 7.4 is stronger compared to the other two subclasses. However, due to the demonstrated long serum half-life of bIgG2a-based mAbs, the stronger binding of bIgG2a at the pH required to return the antibody to circulation (pH 7.4) is not a concern.

[0331] [000352] bIgG2-based mAbs have a serum half-life of up to 21 days in calves, which is significantly longer than most human therapeutic mAbs. Bovid IgG2a has a stronger affinity for bFcRn at pH 6 than bIgG1a. Therefore, the bIgG3a subclass may have a shorter serum half-life than bIgG2a. Thus, it is desirable to increase the affinity of bIgG3a for bFcRn to extend its in vivo half-life to be comparable to that of bIgG2a. [Table 13]

[0332] [000353] To improve affinity for bFcRn, a point mutation was introduced into bIgG3a (Arg433His). This mutation was based on alignment with bIgG1a and bIgG2a, as shown in Figure 2. In addition, the human IgG3 allotype with His435 had a dramatically longer serum half-life than the allotype with Arg435, and this residue position is in the same region as arginine in bIgG3, just two residues upstream from human arginine: HEALHNRY for hIgG3 and HEALRNHY for bIgG3 (Figure 2).

[0333] [000354] In order to improve the affinity for bFcRn, an R433H mutant bIgG3a mAb was generated as described above. Figure 22 shows the constant region alignment of the bIgG3a wild-type recombinant mAb with the R433H mutant.

[0334] [000355] As described in the above examples, a Biacore SPR binding assay was designed to test the affinity of bovine IgG subclasses for bovine FcRn.

[0335] [000356] The bIgG3a_R433H mutant binds to bFcRn with five times higher affinity than bIgG3a wild-type at pH 6, and the mutant retains negligible binding to bFcRn at pH 7.4 (Table 13). Therefore, the R433H mutant may improve the serum half-life.

[0336] [000357] Although preferred embodiments of the present invention have been described, it should be understood that the present invention is not limited to specific embodiments and that various changes and modifications can be made by those skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

Claims

1. 1. A modified IgG comprising a bovine IgG constant domain comprising at least one amino acid substitution compared to a wild-type bovine IgG constant domain, wherein the substitution is at amino acid residue 216, 234, 235, 237, 270, 329, 330, 331, 432, 434, 437, or 433, as numbered according to the Eu index in Kabat.

2. The modified IgG of claim 1, wherein the substitution is D216E, P234A, L235A, G237A, D270E, P329S, A330S, P331S, L432A, N434A, or T437A.

3. The modified IgG of claim 1 , wherein the modified IgG is a bovine or bovinized IgG.

4. The modified IgG of claim 1 , wherein the IgG constant domain comprises a CH1 domain or a hinge region.

5. The modified IgG of claim 1 , wherein the IgG constant domain comprises an Fc constant region having CH2 and CH3 domains.

6. 2. The modified IgG of claim 1, wherein the wild-type bovine IgG constant domain comprises one of the amino acid sequences set forth in SEQ ID NOs: 1-9.

7. A pharmaceutical composition comprising the modified IgG of claim 1 and a pharma- ceutically acceptable carrier.

8. A kit comprising, in a container, the modified IgG of claim 1 and instructions for use.

9. A polypeptide comprising the modified IgG of claim 1.

10. A vector comprising a nucleic acid sequence encoding any one of the amino acid sequences set forth in SEQ ID NOs: 10 to 12, 14 to 25, and 27 to 31.

11. An isolated cell comprising the vector of claim 10.

12. A fusion molecule comprising a bovine IgG constant domain fused to an agent, said bovine IgG constant domain comprising a modified IgG of claim 1.

13. The modified IgG described in claim 1, wherein the substitution is R433H.